



Joel Neal, MD, PhD

Professor of Medicine (Oncology)
Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Comprehensive Cancer Center**

875 Blake Wilbur Dr Rm B

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 725-5849

ACADEMIC CONTACT INFORMATION

- **Research Admin**

Email thoracicmedoncadmin@stanford.edu

Tel 650-498-6000

Bio

BIO

Dr. Neal holds a medical degree and a doctoral degree in Tumor Cell Biology from Northwestern University in Chicago, Illinois. Subsequently, he completed a fellowship in oncology, rotating through the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts. He is currently a Professor in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Neal's primary clinical interest is in thoracic oncology. In addition to maintaining an active practice, he focuses on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer and mesothelioma. He has published dozens of articles in the field of thoracic oncology, including in *Lancet Oncology*, *Nature Medicine*, and the *Journal of Clinical Oncology*. He is a member of the International Association of the Study of Lung Cancer (IASLC), is a study chair and thoracic core committee member within the ECOG-ACRIN cooperative group, and has presented at a number of American Society of Clinical Oncology (ASCO) annual meetings.

CLINICAL FOCUS

- Cancer > Thoracic Oncology
- Thoracic Oncology
- Lung Cancer
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor - Univ Med Line, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Residency: Beth Israel Deaconess Medical Center Internal Medicine Residency (2007) MA
- Medical Education: Northwestern University Feinberg School of Medicine (2004) IL
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2010) MA

- Board Certification: Medical Oncology, American Board of Internal Medicine (2010)

LINKS

- Publications: <https://www.ncbi.nlm.nih.gov/pubmed/?term=neal%2C+joel+w>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

I am a thoracic oncologist who cares for patients with non-small cell lung cancer, malignant mesothelioma, and other thoracic malignancies. I design and conduct clinical trials of novel therapies in collaboration with other researchers and pharmaceutical companies. These generally focus on two areas, 1) targeted therapies against particular mutations in cancers (for example EGFR, ALK, ROS1, HER2, KRAS, MET, and others) and 2) the emerging field of immunotherapy in cancer, using anti PD-1/PD-L1 therapies in combination with other agents, and also developing cellular therapies. I also collaborate with other researchers on campus to apply emerging technologies to cancer therapy, for example, circulating tumor DNA detection. Additionally, in my role as the Cancer Center IT Medical Director, I coordinate projects relating to our use of the electronic health record to improve provider efficiency and facilitate patient care.

CLINICAL TRIALS

- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer, Recruiting
- A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1), Recruiting
- Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E), Recruiting
- Molecular Analysis of Thoracic Malignancies, Recruiting
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer, Recruiting
- Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC, Recruiting
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors, Not Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors, Not Recruiting
- A Phase 1/2 Study to Evaluate MEDI4736, Not Recruiting
- A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR], Not Recruiting
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer, Not Recruiting
- A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1), Not Recruiting
- A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer, Not Recruiting
- Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation, Not Recruiting
- Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer, Not Recruiting
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026), Not Recruiting
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery, Not Recruiting

- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer, Not Recruiting
- Crizotinib in Treating Patients With Stage IB-IIIa Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial), Not Recruiting
- Erlotinib and Mometotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC), Not Recruiting
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer, Not Recruiting
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIa Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial), Not Recruiting
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR, Not Recruiting
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations, Not Recruiting
- Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC, Not Recruiting
- Genetic Testing in Screening Patients With Stage IB-IIIa Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial), Not Recruiting
- Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients, Not Recruiting
- LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib, Not Recruiting
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer, Not Recruiting
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer, Not Recruiting
- MAGE A10c####T for Advanced NSCLC, Not Recruiting
- Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIa Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial), Not Recruiting
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor, Not Recruiting
- PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients, Not Recruiting
- Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer, Not Recruiting
- Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy, Not Recruiting
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer, Not Recruiting
- Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer, Not Recruiting
- Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors, Not Recruiting
- Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer, Not Recruiting
- Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma, Not Recruiting
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab, Not Recruiting
- Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy, Not Recruiting
- RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT), Not Recruiting
- SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer, Not Recruiting
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer, Not Recruiting
- Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination, Not Recruiting
- Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours, Not Recruiting

- Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy, Not Recruiting
- Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC), Not Recruiting
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors, Not Recruiting
- Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010), Not Recruiting
- Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors, Not Recruiting
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010], Not Recruiting
- Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients, Not Recruiting
- TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations, Not Recruiting
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer, Not Recruiting
- Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial), Not Recruiting
- TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy, Not Recruiting
- Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141), Not Recruiting
- A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies, Not Specified
- Adoptive Cell Therapy Long-term Follow-up (LTFU) Study, Not Specified
- An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer, Not Specified

Publications

PUBLICATIONS

- **First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Gray, J. E., Neal, J. W., Patel, J. D., Liu, S. V., Veillon, R., Reck, M., Cappuzzo, F., Cobo, M., Reguart, N., Fuentes Pradera, J., Cho, B. C., Mok, T., Mekan, et al
2026
- **Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.** *JCO precision oncology*
Terashima, R., Fan, J., Gunturkun, F., Nieda, G., Fan, X., Rodriguez, E. M., Tan, A. X., Thottunkal, S., Shaw, M., Su, C. C., Khan, A., Ding, V. Y., Luo, et al
2026; 10 (4): e2500884
- **Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers.** *JCO precision oncology*
Miao, E. A., Yeap, B., Daher, S., Lomibao, M., Sun, F., Keogh, R., Lambden, J., Reyes, A., Peterson, J. L., Liang, J., Liu, A., Do, A., Lee, et al
2026; 10 (3): e2501148
- **SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC**
Nadal, E., Chافت, J., Garassino, M., Gray, J., Lee, S., Lee, J. M., Mazieres, J., Neal, J., Negrao, M., Popat, S., Senan, S., Tsuboi, M., Wu, et al
GEORG THIEME VERLAG KG.2026
- **Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.** *Nature communications*

- Manabe, T., Bergo, H. C., Li, Q., Wang, T. S., Severson, P., Miller, N., Lee, C., Yay Donderici, E., Zhang, N., Wu, W., Chou, Y. T., Kerr, D. L., Allegakoen, et al
2026
- **AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer.** *Nature medicine*
Li, Z., Li, Y., Xiang, J., Wang, X., Yang, S., Zhang, X., Eweje, F., Chen, Y., Luo, X., Li, Y., Mulholland, J., Bergstrom, C., Kim, et al
2026
 - **Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.** *Annals of internal medicine*
Su, C. C., Ding, V. Y., Ten Haaf, K., Wu, J. T., Freedman, N. D., Backhus, L. M., Leung, A. N., Lui, N. S., Haiman, C. A., Park, S. L., Neal, J. W., Meza, R., Tammemägi, et al
2025
 - **Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Tomasini, P., Wang, Y., Li, Y., Felip, E., Wu, L., Cui, J., Besse, B., Spira, A. I., Neal, J. W., Goto, K., Baik, C. S., Marmarelis, M. E., Ichihara, et al
2025: JCO2402835
 - **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.** *JTO clinical and research reports*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2025; 6 (12): 100914
 - **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy.** *JTO clinical and research reports*
Aredo, J. V., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W.
2025; 6 (12): 100913
 - **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy** *JTO CLINICAL AND RESEARCH REPORTS*
V. Aredo, J., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W.
2025; 6 (12)
 - **Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC A Multicenter Retrospective Study** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Waliany, S., Roy, S., Pecci, F., Weber, U. M., Sun, F., Arter, Z., Lomibao, M., V. Alessi, J., Nishino, M., Luo, F., Repetto, M., Falcon, C., Do, et al
2025; 23 (12)
 - **Leveraging large language models to extract smoking history from clinical notes for lung cancer surveillance.** *NPJ digital medicine*
Luo, I., Graber-Naidich, A., Zhang, M., Kaushik, R., Nieda, G. M., Chen, T., Gu, B., Choi, E., Ding, V. Y., Gunturkun, F., Satoyoshi, M., Bhat, A., Lee, et al
2025; 8 (1): 731
 - **Subcutaneous (SC) amivantamab (ami) plus chemotherapy (chemo) in EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC) after disease progression on osimertinib (osi)**
Nadal, E., Neal, J., Signorelli, D., Tan, J. L., de Lima, V., Tang, K., Benafif, S., Moskovitz, M. T., Ono, A., Reck, M., Hiret, S., Waqar, S. N., Das, et al
ELSEVIER.2025
 - **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System- Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes** *JTO CLINICAL AND RESEARCH REPORTS*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J.
2025; 6 (12)
 - **Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer** *CLINICAL LUNG CANCER*
Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., Das, M. S.
2025; 26 (7)
 - **First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*

- Reck, M., Patel, J. D., Gray, J. E., Reguart, N., Cobo, M., Pradera, J. F., Felip, E., Cappuzzo, F., Garon, E. B., Neal, J. W., Mekan, S., Safavi, F., Fernando, et al
2025
- **The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Zheng, M. M., Xia, Y., Pan, K., Sun, F., Tan, A. C., Dong, X. R., Tu, H. Y., Tang, L. B., Li, Y. S., Yin, K., Borgeaud, M., Singhal, S., Zhu, et al
2025
 - **Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.** *Research square*
Manabe, T., Bergo, H. C., Li, Q., Wang, T. S., Severson, P., Miller, N., Lee, C., Donderici, E. Y., Zhang, N., Wu, W., Chou, Y. T., Kerr, D. L., Allegakoen, et al
2025
 - **Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study**
Lin, S. H., Okishio, K., Mizutani, H., Lee, J. B., Kim, S., Smith, D., Neal, J. W., Hochmair, M., Davis, K. L., Jimenez, M., Nasirova, F., Kim, Y.
ELSEVIER SCIENCE INC.2025
 - **EVEREST-2: Phase 1/2 Study of Logic-Gated Tmod CAR T A2B694 in Lung Cancer and Other Tumors Expressing MSLN With HLA-A*02 LOH**
Punekar, S., Chachoua, A., Velchetti, V., Hazim, A. Z., Karam, D. P., Marar, R. I., Garon, E. B., Goldman, J. W., Ward, J. P., Park, J. C., Patel, S. P., Gold, K. A., Lou, et al
ELSEVIER SCIENCE INC.2025
 - **SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy**
Nadal, E., Chافت, J., Garassino, M., Gray, J., Lee, S., Lee, J. M., Mazieres, J., Neal, J., Negrao, M. V., Popat, S., Senan, S., Tsuboi, M., Wu, et al
ELSEVIER SCIENCE INC.2025
 - **Large Language Models to Extract Smoking History From Clinical Notes in EHR to Evaluate Lung Cancer Surveillance Strategies**
Luo, I., Graber-Naidich, A., Kaushik, R., Nieda, G. M., Choi, E., Ding, V. Y., Gunturkun, F., Satoyoshi, M., Bhat, A., Chen, T., Zhang, M., Lee, T., Su, et al
ELSEVIER SCIENCE INC.2025
 - **Socioeconomic Inequalities and Lung Cancer Outcomes: Evidence From an Integrated EHR Database and State Cancer Registry Data**
Lee, T. Y., Su, C. C., Choi, E., Ding, V. Y., Satoyoshi, M., Bhat, A., Chen, T., Luo, I., Liu, Y., Henry, S., Backhus, L. M., Ellis-Caleo, T. J., Gomez, et al
ELSEVIER SCIENCE INC.2025
 - **Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK plus NSCLC**
Gerber, D. E., Wang, Y., Langer, C. J., Khullar, O. V., Kozono, D. E., Cornelius, L. A., Forde, P. M., Nwaneri, M. O., Neal, J. W., Talsania, A., Leal, T. A., Patel, M., Donthireddy, et al
ELSEVIER SCIENCE INC.2025
 - **Pivotal ARROS-1 Efficacy and Safety Data: Zidesantinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+NSCLC**
Drilon, A. E., Cho, B. C., Lin, J. J., Solomon, B. J., Lin, C., De Langen, A. J., Felip, E., Neal, J. W., Liu, S. V., Soo, R. A., Kao, S., Wolf, J., Liu, et al
ELSEVIER SCIENCE INC.2025
 - **Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.** *Journal for immunotherapy of cancer*
Cortellini, A., Santo, V., Brunetti, L., Garbo, E., Pinato, D. J., La Cava, G., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., Gettinger, S., Kim, et al
2025; 13 (9)
 - **Nativity status and non-small cell lung cancer outcomes**
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Myall, N. J., Roy, M., Wakelee, H. A.
AMER ASSOC CANCER RESEARCH.2025: B144
 - **Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study.** *Lung cancer (Amsterdam, Netherlands)*
Ahn, M. J., Lin, S. H., Yang, C. T., Lee, J. B., Neal, J. W., Okishio, K., Nishino, K., Smith, D., Rauter, M., Jimenez, M., Nasirova, F., Kim, Y.
2025; 209: 108748

- **Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Sun, F., Banwait, M. K., Singhal, S., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L., Ullah, A. T., Guo, E. W., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, et al
2025; 208: 108747
- **Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast Cancer.** *Cancer reports (Hoboken, N.J.)*
Nagpal, S., Nguyen, K. S., Bertrand, S., Cunanan, K. M., Padda, S. K., Pagtama, J. Y., Tisch, A. H., Coffey, G., Thomas, R. P., Sledge, G. W., Gruber, J., Telli, M. L., Pegram, et al
2025; 8 (9): e70330
- **Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response.** *JTO clinical and research reports*
van 't Erve, I., Blanchard, I., Pagtama, J. Y., Holmes Tisch, A. J., Alizadeh, A. A., Ramchandran, K., Wakelee, H. A., Padda, S. K., Diehn, M., Neal, J. W.
2025; 6 (9): 100877
- **Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy.** *JACC. CardioOncology*
Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M., Lee, C., You, J., Fazal, M., Le Guen, Y., Batchelder, R., Reddy, S. A., Katsumoto, T., Ramchandran, et al
2025
- **Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.** *Clinical lung cancer*
Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., Das, M. S.
2025
- **Smoking Trends in KRAS-Mutated Non-Small Cell Lung Cancer at a Tertiary Referral Center**
Aredo, J., Neal, J. W., Ramchandran, K. J., Das, M. S., Myall, N. J., Wakelee, H. A.
ELSEVIER SCIENCE INC.2025
- **Development and implementation of cancer clinical trial patient screening using an electronic medical record-integrated trial matching system.** *BMJ health & care informatics*
Bui, N., Nika, A., Montoya, M., Lopez, A., Newman, J., Vaddadi, M., Guli, R., Rodin, M., Robinson, A., Rosenthal, E., Artandi, S. E., Ather, S., Pang, et al
2025; 32 (1)
- **Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.** *Journal for immunotherapy of cancer*
Miller, N. J., Baik, C., Neal, J. W., Sun, F., Santana-Davila, R., Lee, S., Eaton, K. D., Martins, R. G., Rodriguez, C., Wakelee, H., Padda, S. K., Sotillo, E., Konnick, et al
2025; 13 (7)
- **Automatic Abstraction of Computed Tomography Imaging Indication Using Natural Language Processing for Evaluation of Surveillance Patterns in Long-Term Lung Cancer Survivors.** *JCO clinical cancer informatics*
Khan, A., Choi, E., Su, C., Graber-Naidich, A., Henry, S., Satoyoshi, M. L., Bhat, A., Kurian, A. W., Liang, S. Y., Neal, J., Gould, M., Leung, A., Wakelee, et al
2025; 9: e2400279
- **FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases.** *Translational cancer research*
Sun, F., Neal, J. W., Myall, N. J.
2025; 14 (6): 3295-3301
- **FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases** *TRANSLATIONAL CANCER RESEARCH*
Sun, F., Neal, J. W., Myall, N. J.
2025
- **Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

Mack, P. C., Redman, M. W., Tukachinsky, H., Kozono, D. E., Minichiello, K., Dragnev, K. H., Tolba, K. A., Neal, J. W., Madison, R. W., Waqar, S. N., Aggarwal, C., Hirsch, F. R., Patel, et al
2025

- **Unique mutational landscape and therapeutic implications in non-small cell lung cancer with comorbid fibrotic interstitial lung disease**
Michalski, J., Neal, J. W.
LIPPINCOTT WILLIAMS & WILKINS.2025: 8061
- **Oncoshare-Lung: Novel three-way linkage of neighboring academic and community medical centers to state cancer registry for lung cancer.**
Su, C., Choi, E., Satoyoshi, M., Bhat, A., Chen, T., Ding, V., Khan, A., Lee, T., Wu, J., Henry, S., Desai, M., Neal, J. W., Backhus, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: e23292
- **S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent *KRAS* mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).**
Padda, S., Redman, M., Gerber, D. E., Minichiello, K., Mehta, D. R., Mashru, S. H., Hakim, H., Brahmer, J. R., Bradley, J. D., Stinchcombe, T., Gray, J. E., Kelly, K., Kozono, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study.**
Le, X., Piotrowska, Z., Spira, A. I., Baik, C. S., Baggstrom, M., Falchook, G., Neal, J. W., Gadgeel, S. M., Lopes, G., Johnson, M., Riess, J. W., Nguyen, D., Morelli, et al
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS8665
- **Digital pathology-based AI spatial biomarker to predict outcomes for immune checkpoint inhibitors in advanced non-small cell lung cancer.**
Eweje, F., Li, Z., Li, Y., Bergstrom, C. P., Kim, T., Olguin, F., Willens, S., Gopaulchan, M., Nirschl, J., Neal, J. W., Diehn, M., Li, R.
LIPPINCOTT WILLIAMS & WILKINS.2025: 8569
- **Safety and Tolerability of Lete-cel in NSCLC-Reply.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Altan, M., Lopes, G., Hiltermann, T. J., Govindan, R., Villaruz, L. C., Calvo, E., Edelman, M. J., Furqan, M., Neal, J., Felip, E., Carlisle, J. W., Heymach, J. V., O'Carbhaill, et al
2025; 31 (9): 1810-1811
- **Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.** *Cancer discovery*
Moding, E. J., Shahrokh Esfahani, M., Jin, C., Hui, A. B., Nabet, B. Y., Liu, Y., Chabon, J. J., Binkley, M. S., Kurtz, D. M., Hamilton, E. G., Chaudhuri, A. A., Liu, C. L., Li, et al
2025: OF1-OF21
- **An ultrasensitive method for detection of cell-free RNA.** *Nature*
Nesselbush, M. C., Luca, B. A., Jeon, Y. J., Jabara, I., Meador, C. B., Garofalo, A., Binkley, M. S., Hui, A. B., van 't Erve, I., Xu, N., Shi, W. Y., Liu, K. J., Sugio, et al
2025
- **Unveiling the Anti-Tumor Activity of Exarafenib in BRAF-Mutated NSCLC Through Genomic Analysis and Combined Preclinical, Clinical Outcomes**
Manabe, T., Wang, T., Severson, P., Miller, N., Lee, C., Donderici, E., Zhang, N., Bergo, H. C., Chou, Y., Kerr, D. L., Wu, W., Grandinetti, K. B., Soroceanu, et al
ELSEVIER SCIENCE INC.2025: S1-S2
- **Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.** *Nature*
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Cobo, A. G., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., Juan, J. M., Min, C., Yu, et al
2025
- **Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis.** *Circulation research*
Huang, Y. V., Sun, Y., Chou, H., Wagner, N., Vitale, M. R., Bayer, A. L., Xu, B., Lee, D., Lin, Z., Branche, C., Waliyany, S., Neal, J. W., Wakelee, et al
2025
- **Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.** *Journal for immunotherapy of cancer*

- Cortellini, A., Brunetti, L., Di Fazio, G. R., Garbo, E., Pinato, D. J., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., Gettinger, S., Kim, S. Y., Jayakrishnan, et al
2025; 13 (2)
- **Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies.** *Cardiology clinics*
Sayegh, H., Zagouras, A., Neal, J. W., Witteles, R. M., Zhu, H., Waliany, S.
2025; 43 (1): 31-42
 - **Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors** *JTO CLINICAL AND RESEARCH REPORTS*
Myall, N. J., Whisenant, J. G., Neal, J. W., Iams, W. T., Reckamp, K. L., York, S., Berry, L. D., Shyr, Y., Horn, L., Wakelee, H. A., Padda, S. K.
2025; 6 (2)
 - **Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.** *JTO clinical and research reports*
Myall, N. J., Whisenant, J. G., Neal, J. W., Iams, W. T., Reckamp, K. L., York, S., Berry, L. D., Shyr, Y., Horn, L., Wakelee, H. A., Padda, S. K.
2025; 6 (2): 100757
 - **First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Janne, P. A., Wang, B., Cho, B. C., Zhao, J., Li, J., Hochmair, M., Peters, S., Besse, B., Pavlakis, N., Neal, J. W., Kato, T., Wu, Y., Nguyen, et al
2025: JCO2401269
 - **A vision-language foundation model for precision oncology.** *Nature*
Xiang, J., Wang, X., Zhang, X., Xi, Y., Eweje, F., Chen, Y., Li, Y., Bergstrom, C., Gopaulchan, M., Kim, T., Yu, K. H., Willens, S., Olguin, et al
2025
 - **Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Besse, B., Goto, K., Wang, Y., Lee, S. H., Marmarelis, M. E., Ohe, Y., Caro, R. B., Kim, D. W., Lee, J. S., Cousin, S., Ichihara, E., Li, Y., Paz-Ares, et al
2025
 - **Unveiling Exarafenib's Role in BRAF-Mutated NSCLC Through Genomic Analysis and Combined Preclinical, Clinical Outcomes**
Manabe, T., Severson, P., Wang, T., Miller, N., Zhang, N., Donderici, E., Soroceanu, L., Lee, C., Pelham, R., Chou, Y., Khanna, V., Neal, J., Chen, et al
WILEY.2025: 1293
 - **Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC** *JTO CLINICAL AND RESEARCH REPORTS*
Aredo, J., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A., Salahudeen, A., Kwong, B., Berry, G. J., Guo, H., Cunanan, K., Vali, S., Pancirer, et al
2024; 5 (12)
 - **Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.** *Cancer medicine*
Waliany, S., Nagasaka, M., Park, L., Lam, C., Jiang, Z., Lin, F., Neal, J. W.
2024; 13 (24): e70272
 - **Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study** *CLINICAL LUNG CANCER*
Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., Kurian, A. W., Han, S. S.
2024; 25 (8)
 - **Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stage III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): Final analysis of a global real-world (rw) study**
Ahn, M., Lin, S. H., Yang, C., Lee, J. B., Neal, J., Okishio, K., Nishino, K., Smith, D., Rauter, M., Jimenez, M., Nagar, S. P., Nasirova, F., Kim, et al
ELSEVIER.2024: S1625-S1626
 - **Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.** *JTO clinical and research reports*

- Aredo, J. V., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A. B., Salahudeen, A., Kwong, B., Berry, G. J., Guo, H. H., Cunanan, K., Vali, S., Pancirer, et al
2024; 5 (12): 100741
- **Safety and Tolerability of Letretresgene Autoleucl (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Altan, M., Lopes, G., Hiltermann, T. J., Govindan, R., Villaruz, L. C., Calvo, E., Edelman, M. J., Furqan, M., Neal, J., Felip, E., Carlisle, J. W., Heymach, J. V., O'Ceirbhaill, et al
2024
 - **Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care.** *Translational lung cancer research*
Wu, F., Zeng, Y., Neal, J. W.
2024; 13 (10): 2853-2855
 - **The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-Small Cell Lung Cancer.** *The Annals of thoracic surgery*
Kim, S. S., Cooke, D. T., Kidane, B., Tapias, L. F., Lazar, J. F., Awori Hayanga, J. W., Patel, J. D., Neal, J. W., Abazeed, M. E., Willers, H., Shrager, J. B.
2024
 - **CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.** *Nature*
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Cobo, A. G., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., Juan, J. M., Min, C., Yu, et al
2024
 - **Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.** *JTO clinical and research reports*
Neal, J. W., Santoro, A., Gonzalez-Cao, M., Lim, F. L., Fang, B., Gentzler, R. D., Goldschmidt, J., Khrizman, P., Proto, C., Patel, S., Puri, S., Liu, S. V., Massarelli, et al
2024; 5 (10): 100666
 - **Sacituzumab Govitecan plus Pembrolizumab plus Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study**
Gray, J., Neal, J., Patel, J. D., Liu, S. V., Girard, N., Reck, M., Cappuzzo, F., Cobo Dols, M., Reguart, N., Fuentes Pradera, J., Cho, B. C., Li, M., Mekan, et al
ELSEVIER SCIENCE INC.2024: S27
 - **Central Nervous System (CNS) Progression on CNS Penetrable ALK TKI: Real-World Practice Patterns and Patient Outcomes**
Singhal, S., Hui, C., Neal, J., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H., Myall, N.
ELSEVIER SCIENCE INC.2024: S200-S201
 - **Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFRMutated NSCLC**
Sun, F., Banwait, M. K., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L. A., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, K. J., Roy, M., Diehn, M., Myall, et al
ELSEVIER SCIENCE INC.2024: S196-S197
 - **Impact of Using Smoking Duration in Place of PackYears as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities**
Su, C. C., Ding, V. Y., Haaf, K. T., Wu, J. T., Freedman, N. D., Backhus, L. M., Leung, A. N., Lui, N. S., Haiman, C. A., Park, S. L., Neal, J. W., Meza, R., Tammemagi, et al
ELSEVIER SCIENCE INC.2024: S49
 - **A Phase 2 Single-Arm Trial of High -Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non Small Cell Lung Cancer**
Kotha, N. V., Vitzthum, L., Chin, A. L., Jackson, S., Pratapneni, A., Le-Budka, M. L., Brown, E., Barnick, K., Wakelee, H. A., Das, M., Ramchandran, K. J., Myall, N., Padda, et al
ELSEVIER SCIENCE INC.2024: S60
 - **A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer.** *International journal of radiation oncology, biology, physics*
Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L., Jackson, S., 't Erve, I. v., Pratapneni, A., Le-Budka, M. L., Wong, S., Brown, E., Barnick, K., Wakelee, H. A., Das, et al
2024

- **Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Nassar, A. H., Jayakrishnan, R., Feng, J., Shepherd, F., Adib, E., Cheung, J. M., Lin, J. J., Liu, Y., Lin, S. H., Parikh, K., Sridhar, A., Shakya, P., Dilling, et al
2024
- **Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study.** *Clinical lung cancer*
Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., Kurian, A. W., Han, S. S.
2024
- **Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer** *CLINICAL LUNG CANCER*
Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., Neal, J. W.
2024; 25 (6): 550-559
- **Phase III ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours**
Besse, B., Drilon, A. E., Cho, B. C., Camidge, D. R., Neal, J., Lin, C., Liu, S. V., Nagasaka, M., Kao, S., Felip, E., Van der Wekken, A. J., Lin, C. C., Bauman, et al
ELSEVIER.2024: S804-S805
- **Racial and Ethnic Differences in Second Primary Lung Cancer Risk among Lung Cancer Survivors.** *JNCI cancer spectrum*
Choi, E., Hua, Y., Su, C. C., Wu, J. T., Neal, J. W., Leung, A. N., Backhus, L. M., Haiman, C., Le Marchand, L., Liang, S., Wakelee, H. A., Cheng, I., Han, et al
2024
- **Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study.** *Journal of thoracic disease*
Wang, J., Liang, S., Xu, L., Kong, Y., Seki, N., Ganti, A. K., Neal, J. W., Li, J., Xu, F., Li, K., Xu, Y., Wu, L., Chen, et al
2024; 16 (6): 3897-3908
- **Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.** *Clinical lung cancer*
Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., Neal, J. W.
2024
- **Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC**
Miller, N. J., Baik, C. S., Neal, J. W., Houghton, A., Nair, V. S., Santana-Davila, R., Lee, S., Eaton, K. D., Martins, R. G., Wakelee, H. A., Padda, S., Chiou, S., Tseng, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2**
Cho, B., Wang, Y., Felip, E., Cui, J., Spira, A. I., Neal, J. W., Baik, C., Marmarelis, M., Ichihara, E., Lee, J., Lee, S., Yang, J., Michels, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Sacituzumab govitecan (SG) plus pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02**
Patel, J. D., Cho, B., Cobo, M., Cabanillas, R., Vicente, D., Pradera, J., Garon, E. B., Mok, T. S. K., Cappuzzo, F., Neal, J. W., Mekan, S., Safavi, F., Fernando, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK plus non-small cell lung cancer (NSCLC)**
Jayakrishnan, R., Nassar, A., Shepherd, F. A., Lin, J., Lin, S. H., Shakya, P., Dilling, T. J., Bar, J., Grohe, C., Gupta, S., Fitzgerald, B., Adib, E., Sankar, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.** *The oncologist*
Neal, J. W., Minichiello, K., Brennick, R., Huang, R. S., Hiemenz, M. C., Amler, C., Patel, J., Herbst, R., Reckamp, K. L., Borghaei, H., Highleyman, L., Redman, M. W., Pasquina, et al
2024

- **CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Neal, J., Pavlakis, N., Kim, S. W., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A., Christoph, D. C., Bearz, A., Quantin, X., Palmero, R., Antic, et al
2024: JCO2302166
- **Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912US patients.** *Cell reports. Medicine*
Liu, R., Wang, L., Rizzo, S., Garmhausen, M. R., Pal, N., Waliyany, S., McGough, S., Lin, Y. G., Huang, Z., Neal, J., Copping, R., Zou, J.
2024: 101444
- **Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., Kaldas, D., Gray, J. E., Dilling, T. J., Neal, J. W., Wakelee, H. A., Liu, Y., Lin, et al
2024
- **HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.** *Clinical lung cancer*
Waliyany, S., Neal, J. W., Engel-Nitz, N., Lam, C., Lin, F., Park, L., Le, L., Nagasaka, M.
2024
- **Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.** *Current treatment options in cardiovascular medicine*
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliyany, S., Neal, J., Witteles, R., Nguyen, P., Cheng, P., Zhu, H.
2023; 25 (12): 715-735
- **Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.** *Scientific reports*
Karacosta, L. G., Pancirer, D., Preiss, J. S., Benson, J. A., Trope, W., Shrager, J. B., Sung, A. W., Neal, J. W., Bendall, S. C., Wakelee, H., Plevritis, S. K.
2023; 13 (1): 21781
- **Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.** *Clinical lung cancer*
Ou, S. I., Prawitz, T., Lin, H. M., Hong, J. L., Tan, M., Proskorovsky, I., Hernandez, L., Jin, S., Zhang, P., Lin, J., Patel, J., Nguyen, D., Neal, et al
2023
- **Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series** *JACC: CardioOncology*
Franquiz, M., Waliyany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., Wakelee, H., Neal, J., Witteles, R., Zhu, H.
2023: 839-841
- **Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.** *Clinical lung cancer*
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., Wakelee, H. A., Neal, J. W., Kovalchuk, N., Chin, A., Diehn, M., Loo, B. W., Xiang, et al
2023
- **Personalized Accelerated ChEroRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.** *Clinical lung cancer*
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., Ramchandran, K., Myall, N. J., Pham, D., Xing, L., Yang, Y., Kovalchuk, N., Yuan, et al
2023
- **Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations**
Al-Obeidi, E., Williams, A., Burkert, N., Pepin, K., Hicks, J. K., Gray, J. E., Stewart, S., Weipert, C., Waqar, S., Spigel, D., Salgia, R., Massarelli, E., Baik, et al
ELSEVIER SCIENCE INC.2023: S489
- **Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.** *JAMA network open*
Choi, E., Su, C. C., Wu, J. T., Aredo, J. V., Neal, J. W., Leung, A. N., Backhus, L. M., Lui, N. S., Le Marchand, L., Stram, D. O., Liang, S. Y., Cheng, I., Wakelee, et al
2023; 6 (11): e2343278

- **Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.** *JAMA network open*
Choi, E., Su, C. C., Wu, J. T., Aredo, J. V., Neal, J. W., Leung, A. N., Backhus, L. M., Lui, N. S., Le Marchand, L., Stram, D. O., Liang, S. Y., Cheng, I., Wakelee, et al
2023; 6 (11): e2343278
- **Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.** *JAMA oncology*
Choi, E., Ding, V. Y., Luo, S. J., Ten Haaf, K., Wu, J. T., Aredo, J. V., Wilkens, L. R., Freedman, N. D., Backhus, L. M., Leung, A. N., Meza, R., Lui, N. S., Haiman, et al
2023
- **Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.** *Cancer*
Choi, E., Luo, S. J., Ding, V. Y., Wu, J. T., Kumar, A. V., Wampfler, J., Tammemägi, M. C., Wilkens, L. R., Aredo, J. V., Backhus, L. M., Neal, J. W., Leung, A. N., Freedman, et al
2023
- **The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group (EA) trials.** *Cancer*
Walter, A. W., Lee, J. W., Streck, J. M., Gareen, I. F., Herman, B. A., Kircher, S. M., Carlos, R. C., Kumar, S. K., Mayer, I. A., Saba, N. F., Fenske, T. S., Neal, J. W., Atkins, et al
2023
- **Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations.** *JTO clinical and research reports*
Ou, S. I., Lin, H. M., Hong, J. L., Yin, Y., Jin, S., Lin, J., Mehta, M., Nguyen, D., Neal, J. W.
2023; 4 (10): 100558
- **CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC**
Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., Roy, M., Huang, J., Pollom, E., Myall, N.
ELSEVIER SCIENCE INC.2023: E110
- **Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors**
Ivanovic, M., Chan, A., Franquiz, M., Xu, S., Lee, C., Fazal, M., You, J., Witteles, R., Neal, J., Wu, S., Walianny, S., Zhu, H.
WILEY.2023: 2087-2089
- **CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC.** *International journal of radiation oncology, biology, physics*
Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., Roy, M., Huang, J., Pollom, E., Myall, N.
2023; 117 (2S): e110
- **Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.** *JAMA oncology*
Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., Vitzthum, L. K., Maxim, P. G., Wakelee, H. A., Neal, J., Das, M., Chang, D. T., Kidd, et al
2023
- **Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.** *JAMA network open*
Su, C. C., Wu, J. T., Choi, E., Myall, N. J., Neal, J. W., Kurian, A. W., Stehr, H., Wood, D., Henry, S. M., Backhus, L. M., Leung, A. N., Wakelee, H. A., Han, et al
2023; 6 (9): e2335813
- **Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).** *JCO precision oncology*
Vaidya, R., Unger, J. M., Qian, L., Minichiello, K., Herbst, R. S., Gandara, D. R., Neal, J. W., Leal, T. A., Patel, J. D., Dragnev, K. H., Waqar, S. N., Edelman, M. J., Sigal, et al
2023; 7: e2300218
- **Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.** *Clinical lung cancer*
Wolf, J., Souquet, P. J., Goto, K., Cortot, A., Baik, C., Heist, R., Kim, T. M., Han, J. Y., Neal, J. W., Mansfield, A. S., Gilloteau, I., Nwana, N., Waldron-Lynch, et al
2023

- **Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?** *Translational lung cancer research*
Patel, S. R., Neal, J. W.
2023; 12 (7): 1631-1635
- **Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*
Streck, J. M., Lee, J., Walter, A. W., Rosen, R. L., Gareen, I. F., Kircher, S. M., Herman, B. A., Carlos, R. C., Kumar, S., Mayer, I. A., Saba, N. F., Fenske, T. S., Neal, et al
2023
- **Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Bestvina, C. M., Garassino, M. C., Neal, J. W., Wakelee, H. A., Diehn, M., Vokes, E. E.
2023: JCO2300258
- **Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?** *TRANSLATIONAL LUNG CANCER RESEARCH*
Patel, S. R., Neal, J. W.
2023
- **EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)**
Nassar, A., Adib, E., Feng, J., Aredo, J. V., Parikh, K., Harris, J., Manana, A., Ragavan, M., Lin, J., Piotrowska, Z., Fitzgerald, B., Grohe, C., Sankar, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).**
Padda, S., Redman, M., Gerber, D. E., Stinchcombe, T., Waqar, S., Leal, T., Minichiello, K., Reckamp, K. L., Herbst, R. S., Borghaei, H., Brahmer, J. R., Gray, J., Kelly, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: TPS9143
- **EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).**
Nassar, A., Adib, E., Feng, J., Aredo, J. V., Parikh, K., Harris, J., Velazquez Manana, A. I., Ragavan, M., Lin, J., Piotrowska, Z., Fitzgerald, B., Grohe, C., Sankar, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.**
Mack, P. C., Redman, M., Kozono, D. E., Callis, S., Tukachinsky, H., Tolba, K. A., Neal, J. W., Waqar, S., Dragnev, K. H., Aggarwal, C., Hirsch, F. R., Patel, J. D., Herbst, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)**
Neal, J. W., Li, Y., Yu, Z., Fram, R. J., Danes, C., Vincent, S., Piotrowska, Z.
LIPPINCOTT WILLIAMS & WILKINS.2023: 9082
- **ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).**
Padda, S., Redman, M., Gerber, D. E., Stinchcombe, T., Waqar, S., Leal, T., Minichiello, K., Reckamp, K. L., Herbst, R. S., Borghaei, H., Brahmer, J. R., Gray, J., Kelly, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)**
Neal, J. W., Li, Y., Yu, Z., Fram, R. J., Danes, C., Vincent, S., Piotrowska, Z.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.**

- Girard, N., Cho, B., Spira, A. I., Shu, C. A., Sanborn, R. E., Neal, J. W., Marmarelis, M., Sabari, J. K., Waqar, S., Nagasaka, M., Yang, J., Lu, S., Kambuj, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP**
Mack, P. C., Redman, M., Kozono, D. E., Callis, S., Tukachinsky, H., Tolba, K. A., Neal, J. W., Waqar, S., Dragnev, K. H., Aggarwal, C., Hirsch, F. R., Patel, J. D., Herbst, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
 - **Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.** *The Lancet. Digital health*
Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjehromi, M., Qin, K., Sujit, S. J., Lu, X., Young, E., Al-Tashi, Q., Qureshi, R., Wu, et al
2023
 - **Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.** *Clinical lung cancer*
Bodor, J. N., Patel, J. D., Wakelee, H. A., Levy, B. P., Borghaei, H., Pellini, B., Costello, M. R., Dowell, J. E., Finley, G., Huang, C. H., Neal, J. W., Nieva, J. J., Puri, et al
2023
 - **Dissecting metastasis using preclinical models and methods.** *Nature reviews. Cancer*
Hebert, J. D., Neal, J. W., Winslow, M. M.
2023
 - **Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., Neal, J. W., Wakelee, H. A., Ramchandran, K., Gensheimer, M. F., Diehn, M., Chin, A. L., Loo, et al
2023
 - **Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.** *JTO clinical and research reports*
Sun, T. Y., Nguyen, B., Chen, S. B., Natkunam, Y., Padda, S., van de Rijn, M., West, R., Neal, J. W., Wakelee, H., Riess, J. W.
2023; 4 (4): 100498
 - **CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) plus cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy**
Neal, J., Pavlakis, N., Kim, S., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A., Christoph, D. C., Bearz, A., Quantin, X., Palmero, R., Antic, et al
ELSEVIER SCIENCE INC.2023: S39-S40
 - **Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.** *Lung cancer (Amsterdam, Netherlands)*
Ou, S. I., Lin, H. M., Hong, J. L., Yin, Y., Jin, S., Lin, J., Mehta, M., Zhang, P., Nguyen, D., Neal, J. W.
2023; 179: 107186
 - **Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.** *Frontiers in oncology*
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., Soltys, S. G., Pollom, E. L., Chin, A., Vitzthum, L., Wakelee, H. A., Padda, S. K., Ramchandran, et al
2023; 13: 1139940
 - **Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Grant, M. J., Aredo, J. V., Starrett, J. H., Stockhammer, P., van Alderwerelt van Rosenburgh, I. K., Wurtz, A., Piper-Vallillo, A. J., Piotrowska, Z., Falcon, C., Yu, H. A., Aggarwal, C., Scholes, D., Patil, et al
2023
 - **Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.** *JTO clinical and research reports*
Ji, J., Aredo, J. V., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., Stewart, S., Cobb, R., Wakelee, H. A., Blakely, C. M., Wong, M. L., Gubens, M. A., Madani, et al
2023; 4 (3): 100459
 - **Second Primary Lung Cancer among Lung Cancer Survivors Who Never Smoked**

- Choi, E., Su, C., Wu, J., Aredo, J., Neal, J., Leung, A., Backhus, L., Marchand, L., Liang, S. Y., Cheng, I., Wakelee, H., Han, S.
ELSEVIER SCIENCE INC.2023: E1
- **Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.** *JACC. CardioOncology*
Waliyany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., Neal, J. W.
2023; 5 (1): 85-98
 - **Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research** *Current Treatment Options in Cardiovascular Medicine*
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliyany, S., Neal, J., Witteles, R., Nguyen, P., Cheng, P., Zhu, H.
2023
 - **Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report** *ANNALS OF TRANSLATIONAL MEDICINE*
Liang, L., Zhang, X., Ke, X., Song, Y., Brcic, L., Neal, J. W., Xu, G., Chen, C.
2022
 - **The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity.** *JACC. CardioOncology*
Huang, Y. V., Waliyany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., Fan, A. C., Maecker, H. T., Nguyen, P. K., Wu, S. M., Zhu, H.
2022; 4 (5): 629-634
 - **Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report.** *Annals of translational medicine*
Liang, L., Zhang, X., Ke, X., Song, Y., Brcic, L., Neal, J. W., Xu, G., Chen, C.
2022; 10 (24): 1407
 - **Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.** *Cancer treatment and research communications*
Aredo, J. V., Wakelee, H. A., Hui, A. B., Padda, S. K., Joshi, N. D., Guo, H. H., Chaudhuri, A., Diehn, M., Loo, B. W., Neal, J. W.
2022; 33: 100659
 - **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022: OP2200128
 - **PROVIDER INSIGHTS ON MANAGING PATIENTS ON IMMUNOTHERAPY, BARRIERS TO CLINICAL TRIALS, AND BIOMARKER TESTING PREFERENCES**
Ackbarali, T., Neal, J., Janjigian, Y., Overman, M.
BMJ PUBLISHING GROUP.2022: A970
 - **Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2**
Cho, B. C., Wang, Y., Li, Y., Wu, L., Besse, B., Marmarelis, M. E., Goto, K., Lee, J., Lee, S., Zhang, Y., Neal, J., Curtin, J., Bauml, et al
ELSEVIER.2022: S1566
 - **Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.** *Journal of neuro-oncology*
Hui, C., Qu, V., Wang, J. Y., von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lu, J. T., Li, G., Hayden-Gephart, M., Wakelee, H., Neal, J., Ramchandran, et al
2022
 - **Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes.** *JCO precision oncology*
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., Henry, S., Wood, D., Stehr, H., Ji, H., Nagpal, S., Hayden Gephart, M., Wakelee, et al
2022; 6: e2200220
 - **Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening.**
Gupta, D., Savadamuthu, V., Qin, F., Roy, M., Herring, J., Robinson, A., Terrell, C., Neal, J. W., Lahijani, S., Ramchandran, K.

LIPPINCOTT WILLIAMS & WILKINS.2022: 278

- **Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A (vol 40, pg 2295, 2022) JOURNAL OF CLINICAL ONCOLOGY**
Reckamp, K. L., Redman, M. W., Dragnev, K. H., Minichiello, K., Villaruz, L. C., Faller, B., Al Baghdadi, T., Hines, S., Everhart, L., Highleyman, L., Papadimitrakopoulou, V., Neal, J. W., Waqar, et al
2022; 40 (25): 3002
- **Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC**
Neal, J. W., Lim, F. L., Aix, S. P., Viteri, S., Santoro, A., Spencer, K., Fang, B., Khrizman, P., Kim, J., Subbiah, V., Sudhagoni, R., Samaraweera, L., Andrianova, et al
ELSEVIER SCIENCE INC.2022: S439
- **Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab +/- Platinum in First-Line Metastatic NSCLC**
Reck, M., Liu, S. V., Owen, S. P., Garon, E. B., Neal, J. W., Vicente, D., Mekan, S. F., Safavi, F., Fernando, N., Mok, T. K.
ELSEVIER SCIENCE INC.2022: S448
- **Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC**
Neal, J. W., Lim, F. L., Aix, S. P., Viteri, S., Santoro, A., Spencer, K., Fang, B., Khrizman, P., Kim, J., Subbiah, V., Sudhagoni, R., Samaraweera, L., Andrianova, et al
ELSEVIER SCIENCE INC.2022: S439
- **Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review. Cancer treatment reviews**
Graham, J., Vogel, A., Cheng, A. L., Bjarnason, G. A., Neal, J. W.
2022; 110: 102453
- **Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical radiation oncology**
Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., Yi, E., Ko, R. B., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
2022
- **Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Translational lung cancer research**
Chu, T., Zhang, W., Zhang, B., Zhong, R., Zhang, X., Gu, A., Shi, C., Wang, H., Xiong, L., Lu, J., Qian, J., Zhang, Y., Dong, et al
2022; 11 (7): 1394-1404
- **Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data. Nature medicine**
Liu, R., Rizzo, S., Waliyany, S., Garmhausen, M. R., Pal, N., Huang, Z., Chaudhary, N., Wang, L., Harbron, C., Neal, J., Copping, R., Zou, J.
2022
- **Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation**
Zhu, H., Galdos, F. X., Lee, D., Waliyany, S., Vivian Huang, Y., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., Srinivas, S., Lin, L. L., Witteles, et al
2022: 101161CIRCULATIONAHA121056730
- **Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients**
Choi, E., Lam, V. T., Aredo, J. A., Kumar, A. V., Wampfler, J., Wu, J. T., Christiani, D. C., Cheng, I., Amos, C. I., Hung, R. J., Backhus, L. M., Neal, J. W., Wakelee, et al
AMER ASSOC CANCER RESEARCH.2022
- **Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical lung cancer**
Waliyany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., Li, C., Pagtama, J., Tisch, A. H., Neal, J. W.
2022
- **High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO clinical and research reports**
Piper-Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Luo, J., Carlisle, J. W., Husain, H., Muzikansky, A., Heist, R. S., Rangachari, D., Ramalingam, S. S., Wakelee, H. A., Yu, et al
2022; 3 (6): 100328
- **Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study. Translational lung cancer research**
Lu, D., Ma, Z., Huang, D., Zhang, J., Li, J., Zhi, P., Zhang, L., Feng, Y., Ge, X., Zhai, J., Jiang, M., Zhou, X., Simone, et al

2022; 11 (6): 1119-1131

- **Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials.**
Walter, A., Lee, J., Gareen, I. F., Kircher, S., Herman, B. A., Streck, J. M., Kumar, S., Mayer, I. A., Saba, N. F., Neal, J. W., Atkins, M. B., Hodi, F., Kyriakopoulos, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.**
Grant, M. J., Aredo, J. V., Starrett, J., Wurtz, A., Piotrowska, Z., Piper-Vallillo, A., Yu, H., Falcon, C., Patil, T., Nguyen, C., Aggarwal, C., Scholes, D. G., Li, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC).**
Garon, E. B., Liu, S. V., Owen, S., Reck, M., Neal, J. W., Vicente, D., Mekan, S., Safavi, F., Fernando, N., Mok, T. S. K.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.**
Neal, J. W., Santoro, A., Viteri, S., Aix, S., Fang, B., Lim, F., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Massarelli, E., Patel, S. B., Puri, S., Sudhagoni, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).**
Vaidya, R., Unger, J. M., Qian, L., Minichiello, K., Herbst, R. S., Gandara, D. R., Neal, J. W., Leal, T., Patel, J. D., Dragnev, K. H., Waqar, S., Edelman, M., Sigal, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).**
Ou, S., Prawitz, T., Lin, H., Hong, J., Tan, M., Proskorovsky, I., Hernandez, L., Jin, S., Zhang, P., Lin, J., Patel, J. D., Nguyen, D., Neal, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.** *International journal of radiation oncology, biology, physics*
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., Neal, J., Wakelee, H., Chin, A., Diehn, M., Loo, B. W., Chang, D. T., Pollom, et al
2022
- **Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.** *Journal for immunotherapy of cancer*
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M., Dubinett, S. M., Ferris, A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., Hellmann, M. D., Hirsch, F. R., Johnson, et al
2022; 10 (5)
- **Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.** *Drugs*
Shah, M. P., Neal, J. W.
2022
- **Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.** *European journal of cancer (Oxford, England : 1990)*
Remon, J., Lacas, B., Herbst, R., Reck, M., Garon, E. B., Scagliotti, G. V., Ramlau, R., Hanna, N., Vansteenkiste, J., Yoh, K., Groen, H. J., Heymach, J. V., Mandrekar, et al
2022; 166: 112-125
- **Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer** *TRANSLATIONAL LUNG CANCER RESEARCH*
Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., Xu, X., Tang, X., Wei, T., Zhu, Z., Chu, Q., Neal, J. W., Wu, et al
2022
- **Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.** *Translational lung cancer research*
Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., Xu, X., Tang, X., Wei, T., Zhu, Z., Chu, Q., Neal, J. W., Wu, et al

2022; 11 (2): 295-306

- **The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity** *JACC: CardioOncology*
Huang, Y. V., Waliyany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., Fan, A. C., Maecker, H. T., Nguyen, P. K., Wu, S. M., Zhu, H.
2022; 4 (5): 629–634
- **Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.** *Cancer treatment and research communications*
Aredo, J. V., Wakelee, H. A., Neal, J. W., Padda, S. K.
1800; 30: 100497
- **Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Aredo, J. V., Hellyer, J. A., Neal, J. W., Wakelee, H. A.
2021; 16 (12): 1994-1998
- **A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.** *Cancer chemotherapy and pharmacology*
Padda, S. K., Reckamp, K. L., Koczywas, M., Neal, J. W., Kawashima, J., Kong, S., Huang, D. B., Kowalski, M., Wakelee, H. A.
2021
- **Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.** *Clinical lung cancer*
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., Padda, S. K., Ramchandran, K., Chen, T. T., Sequist, L. V., Piotrowska, Z., Wakelee, H. A.
2021
- **Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.** *JCO precision oncology*
Padda, S. K., Aredo, J. V., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., Neal, J. W., Abbasi, T., Wakelee, H. A.
2021; 5: 153-162
- **A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)**
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., Brown, E., Nguyen, N., Liang, R., Maxim, P. G., Wakelee, H. A., Neal, J. W., Das, et al
ELSEVIER SCIENCE INC.2021: S89-S90
- **Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer**
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., Ko, R. B., Shaheen, S., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
ELSEVIER SCIENCE INC.2021: E435
- **Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents**
Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., Neal, J. W., Ramchandran, K. J., Wakelee, H. A., Shaheen, S., Diehn, M., Chin, A. L., Loo, et al
ELSEVIER SCIENCE INC.2021: E423
- **A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR).** *International journal of radiation oncology, biology, physics*
Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., Brown, E., Nguyen, N., Liang, R., Maxim, P. G., Wakelee, H. A., Neal, J. W., Das, et al
2021; 111 (3S): S89-S90
- **Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.** *International journal of radiation oncology, biology, physics*
Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., Ko, R. B., Shaheen, S., Neal, J. W., Wakelee, H. A., Das, M., Loo, B. W., Diehn, et al
2021; 111 (3S): e435
- **Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.** *Clinical lung cancer*
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., Ramchandran, K., Neal, J. W., Wakelee, H. A.
2021

- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Mobocertinib in EGFR Exon 20 Insertion Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy**
Spira, A., Ramalingam, S., Neal, J., Piotrowska, Z., Mekhail, T., Tsao, A., Gentzler, R., Riely, G., Bazhenova, L., Gadgeel, S., Nguyen, D., Johnson, M., Vincent, et al
ELSEVIER SCIENCE INC.2021: S873-S874
- **Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening**
Su, C., Choi, E., Wu, J., Neal, J., Kurian, A., Backhus, L., Leung, A., Wakelee, H., Han, S.
ELSEVIER SCIENCE INC.2021: S1177-S1178
- **A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes**
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., Henry, S., Wood, D., Stehr, H., Ji, H., Nagpal, S., Gephart, M., Wakelee, et al
ELSEVIER SCIENCE INC.2021: S1177
- **Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. *Journal of patient-reported outcomes***
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., Velazquez, B., Chu, G., Bruzzone, B., Cabot, A., Fisher, G. A., Srinivas, S., Fan, et al
2021; 5 (1): 91
- **Radiological tumor classification across imaging modality and histology. *Nature machine intelligence***
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., Wei, Y., Schönlieb, C. B., Price, S. J., Jaffray, D., Heymach, J., Neal, J. W., Loo, et al
2021; 3: 787-798
- **Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer***
Waliy, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., Myall, N. J., Chen, T., Witteles, R. M., Neal, J. W.
2021
- **Radiological tumour classification across imaging modality and histology *NATURE MACHINE INTELLIGENCE***
Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., Wei, Y., Schönlieb, C., Price, S., Jaffray, D., Heymach, J., Neal, J. W., Loo, et al
2021
- **The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. *Journal of thoracic disease***
Ellis-Caleo, T., Neal, J. W.
2021; 13 (8): 4864-4871
- **EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. *Clinical lung cancer***
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., Neal, J. W.
2021
- **The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer *JOURNAL OF THORACIC DISEASE***
Ellis-Caleo, T., Neal, J. W.
2021
- **Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.**
Ou, S., Lin, H., Hong, J., Yin, Y., Jin, S., Lin, J., Mehta, M., Nguyen, D., Neal, J. W.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.**
Neal, J. W., Kundu, P., Tanaka, T., Enquist, I., Patel, S., Balestrini, A., Wang, J., Newsom-Davis, T., Goto, Y., Pavlakis, N., Kim, S.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management**

- Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., Ramchandran, K., Das, M., Ramsey, M., Bedi, H. S., Sung, A., Raj, R., Anand, et al
AMER THORACIC SOC.2021
- **Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study**
Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., Wakelee, H. A., Ramchandran, K., Das, M., Padda, S. K., Sharifi, H., Mooney, J. J., Tsai, et al
AMER THORACIC SOC.2021
 - **Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib**
White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., Ramchandran, K., Chen, T. T., Wakelee, H.
ELSEVIER SCIENCE INC.2021: S773–S774
 - **Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.**
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z., Das, M., Ramchandran, K. J., Padda, S. K., Neal, et al
AMER ASSOC CANCER RESEARCH.2021
 - **Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabets, B., Almanza, D., Yoo, C., Kurtz, D. M., Owen, S., Backhus, L. M., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER ASSOC CANCER RESEARCH.2021
 - **Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers**
Roy, M., Fardeen, T., Generalova, O., Hall, E., Cunanan, K., Das, M., Neal, J., Padda, S., Wakelee, H. A., Ramchandran, K.
ELSEVIER SCIENCE INC.2021: S170–S171
 - **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*
Waliyan, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137–39
 - **LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis**
Mack, P., Minichielle, K., Redman, M., Tolba, K., Kozono, D., Waqar, S., Chowdhury, A., Dowlati, A., Neal, J., Dragnev, K., Aggarwal, C., Hirsch, F., Kelly, et al
ELSEVIER SCIENCE INC.2021: S163–S164
 - **Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021**
Neal, J., Lim, F., Filip, E., Gentzler, R., Patel, S., Baranda, J., Fang, B., Squillante, C., Simonelli, M., Werneke, S., Curran, D., Ponce Aix, S.
ELSEVIER SCIENCE INC.2021: S230–S231
 - **ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era**
Remon, J., Lacas, B., Herbst, R., Reck, M., Garon, E., Scagliotti, G., Ramlau, R., Hanna, N., Vansteenkiste, J., Yoh, K., Groen, H., Heymach, J., Mandrekar, et al
ELSEVIER SCIENCE INC.2021: S244–S245
 - **Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST**
Su, C. C., Wu, J., Neal, J., Popat, R., Backhus, L., Leung, A., Nagpal, S., Wakelee, H. A., Han, S.
ELSEVIER SCIENCE INC.2021: S149–S150
 - **Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors**
Padda, S., Whisenant, J., Neal, J., York, S., Iams, W., Neuss, M., Reckamp, K., Preiss, J., Berry, L., Shyr, Y., Wakelee, H., Horn, L.
ELSEVIER SCIENCE INC.2021: S626
 - **Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma**
Aredo, J., Wakelee, H. A., Neal, J., Padda, S.
ELSEVIER SCIENCE INC.2021: S619
 - **Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A**

Hirsch, F., Hua, X., Wu, M., Neal, J., Cheng, H., Gettinger, S., Bazhenova, L., Papadimitrakopoulou, V., Borghaei, H., Mack, P., Kelly, K., Herbst, R., Gandara, et al
ELSEVIER SCIENCE INC.2021: S102

- **Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer** *JCO PRECISION ONCOLOGY*
Neal, J. W., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., Ramachandran, K. J., Rangachari, D., Huberman, M. S., Piotrowska, Z., Kris, M. G., Azzoli, C. G., Sequist, et al
2021; 5: 325–32
- **Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer** *JCO PRECISION ONCOLOGY*
Padda, S. K., Aredo, J., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., Neal, J. W., Abbasi, T., Wakelee, H. A.
2021; 5: 153–62
- **Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.** *Immunity*
Chiou, S. H., Tseng, D. n., Reuben, A. n., Mallajosyula, V. n., Molina, I. S., Conley, S. n., Wilhelmy, J. n., McSween, A. M., Yang, X. n., Nishimiya, D. n., Sinha, R. n., Nabet, B. Y., Wang, et al
2021; 54 (3): 586–602.e8
- **Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Su, C. C., Wu, J. T., Neal, J. W., Popat, R. A., Kurian, A. W., Backhus, L. M., Nagpal, S., Leung, A. N., Wakelee, H. A., Han, S. S.
2021
- **Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion**
Ou, S. I., Lin, H. M., Hong, J., Yin, Y., Jin, S., Lin, J., Mehta, M., Nguyen, D., Neal, J. W.
ELSEVIER.2021: S964-S965
- **The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.** *Journal of the National Cancer Institute*
Choi, E., Luo, S. J., Aredo, J. V., Backhus, L. M., Wilkens, L. R., Su, C. C., Neal, J. W., Le Marchand, L., Cheng, I., Wakelee, H. A., Han, S. S.
2021
- **Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.** *JCO oncology practice*
Neal, J. W., Roy, M. n., Bugos, K. n., Sharp, C. n., Galatin, P. S., Falconer, P. n., Rosenthal, E. L., Blayney, D. W., Modaresi, S. n., Robinson, A. n., Ramchandran, K. n.
2021: OP2000473
- **Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Hellyer, J. A., Aredo, J. V., Das, M. n., Ramchandran, K. n., Padda, S. K., Neal, J. W., Wakelee, H. A.
2021
- **Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.** *Clinical lung cancer*
White, M. N., Piotrowska, Z. n., Stirling, K. n., Liu, S. V., Banwait, M. K., Cunanan, K. n., Sequist, L. V., Wakelee, H. A., Hausrath, D. n., Neal, J. W.
2021
- **Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.** *Cancer discovery*
Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z. n., Costa, D. B., Tsao, A. S., Patel, J. D., Gadgeel, S. M., Bazhenova, L. n., Zhu, V. W., West, H. L., Mekhail, et al
2021
- **Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.** *Journal of neuro-oncology*
Zhang, M. n., Rodrigues, A. J., Pollom, E. L., Gibbs, I. C., Soltys, S. G., Hancock, S. L., Neal, J. W., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Chang, S. D., Lim, M. n., Hayden Gephart, et al
2021
- **Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*

- Aredo, J. V., Mambetsariev, I. n., Hellyer, J. A., Amini, A. n., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Naidoo, J. n., Abuali, T. n., Salgia, R. n., Loo, et al
2021
- **Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy**
Aredo, J. V., Hellyer, J. A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Loo, B. W., Diehn, M., Wakelee, H. A.
ELSEVIER SCIENCE INC.2021: S15
 - **Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.** *Clinical chemistry*
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W. n., Fu, A. n., Park, S. M., Gambhir, S. S., Fan, A. C., Neal, J. W., Padda, S. K., Das, et al
2021
 - **Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.** *Clinical lung cancer*
Park, M., Ho, D. Y., Wakelee, H. A., Neal, J. W.
2020
 - **Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)**
Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., Costa, D. B., Tsao, A., Patel, J., Gadgeel, S., Bazhenova, L., Zhu, V. W., West, et al
ELSEVIER.2020: S815–S816
 - **Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)**
Mazieres, J., Tomasini, P., Lusque, A., Boucekine, M., Gautschi, O., Cortot, A. B., Couraud, S., Thai, A., Ng, T., Greillier, L., Veillon, R., Neal, J. W., Popat, et al
ELSEVIER.2020: S826–S827
 - **Comparison of clinical outcomes of patients with METDex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients**
Wolf, J., Neal, J. W., Mansfield, A. S., Doban, V., Kanakamedala, H., Wu, W., Joshi, A., de Jong, E., Giovannini, M., Baik, C. S.
ELSEVIER.2020: S863
 - **A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer**
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C., Hui, A. B., Stehr, H., Goljenola, L., Jin, et al
AMER ASSOC CANCER RESEARCH.2020
 - **Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis**
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., Reddy, S., Heather, W., Neal, J. W., Witteles, R., Maecker, H. T., Davis, M., Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).**
Skoulidis, F., Neal, J. W., Akerley, W. L., Paik, P. K., Papagiannakopoulos, T., Reckamp, K. L., Riess, J. W., Jenkins, Y., Holland, S., Parlati, F., Shen, Y., Whiting, S. H., Rizvi, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.**
Neal, J. W., Lim, F., Felip, E., Gentzler, R. D., Patel, S. B., Baranda, J., Fang, B., Squillante, C., Simonelli, M., Werneke, S., Curran, D., Ponce Aix, S.
AMER SOC CLINICAL ONCOLOGY.2020
 - **Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.**
Horn, L., Lin, H., Padda, S., Aggarwal, C., McCoach, C., Zhu, Y., Yin, Y., Lin, J., Li, S., Feng, Z., Neal, J. W.
AMER SOC CLINICAL ONCOLOGY.2020
 - **High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience.**
Piper-Vallillo, A., Rotow, J. K., Aredo, J., Shaverdashvili, K., Luo, J., Carlisle, J. W., Husain, H., Muzikansky, A., Heist, R., Rangachari, D., Ramalingam, S. S., Wakelee, H. A., Yu, et al

AMER SOC CLINICAL ONCOLOGY.2020

- **Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.**
Ji, J., Aredo, J., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., Stewart, S. L., Cobb, R., Wakelee, H. A., Blakely, C., Wong, M. L., Gubens, M. A., Chen, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.**
Moding, E. J., Esfahani, M., Nabet, B., Liu, Y., Chabon, J. J., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z. X., Das, M., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., Yoo, C., Kurtz, D., Owen, S., Backhus, L., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Discovery of a novel shared tumor antigen in human lung cancer.**
Tseng, D., Chiou, S., Yang, X., Reuben, A., Wilhelmy, J., McSween, A., Conley, S., Sinha, R., Nabet, B., Wang, C., Shrager, J. B., Berry, M. F., Backhus, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model.**
Roy, M., Neal, J. W., Bugos, K., Sharp, C., Falconer, P., Rosenthal, E., Blayney, D. W., Modaressi, S., Robinson, A., Ramchandran, K.
AMER SOC CLINICAL ONCOLOGY.2020
- **Integrating genomic features for non-invasive early lung cancer detection. *Nature***
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Jin, et al
2020; 580 (7802): 245-251
- **Integrating genomic features for non-invasive early lung cancer detection *NATURE***
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., Liu, C., Hui, A. B., Jin, et al
2020
- **Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. *Nature cancer***
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., Jones, C. D., He, J., Qiao, et al
2020; 1 (2): 176-183
- **PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. *Clinical lung cancer***
Zhou, M. n., Joshi, N. n., Raj, K. P., Wakelee, H. n., Neal, J. W.
2020
- **KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. *Cancer discovery***
Binkley, M. S., Jeon, Y. J., Nesselbush, M. n., Moding, E. J., Nabet, B. Y., Almanza, D. n., Kunder, C. n., Stehr, H. n., Yoo, C. H., Rhee, S. n., Xiang, M. n., Chabon, J. J., Hamilton, et al
2020
- **Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. *Annual review of pharmacology and toxicology***
Waliyany, S. n., Lee, D. n., Witteles, R. M., Neal, J. W., Nguyen, P. n., Davis, M. M., Salem, J. E., Wu, S. M., Moslehi, J. J., Zhu, H. n.
2020
- **Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung Cancer. *JCO oncology practice***
Shah, M. P., Neal, J. W.
2020: OP2000612
- **Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer *NATURE CANCER***

- Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Gojenola, L., Jones, C. D., He, J., Qiao, Y., Heymach, et al
2020; 1: 176–183
- **Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.** *Cell*
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. n., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Almanza, D. n., Stehr, H. n., Gojenola, et al
2020
 - **Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer** *NATURE CANCER*
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Gojenola, L., Jones, C. D., He, J., Qiao, Y., Heymach, et al
2020; 1: 176–183
 - **Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.** *Cell*
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. n., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Almanza, D. n., Stehr, H. n., Gojenola, et al
2020
 - **Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)**
Leal, T., Wakelee, H., Reckamp, K. L., Chiappori, A., Oxnard, G. R., Waqar, S. N., Patel, S. P., Blumenschein, G. R., Neal, J. W., Harrow, K., Holzhausen, A., Selvaggi, G., Zhou, et al
ELSEVIER SCIENCE INC.2019: S1171–S1172
 - **Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus) Non-Small Cell Lung Cancer Patients Treated with Ensartinib**
Wakelee, H., Reckamp, K., Leal, T., Chiappori, A., Waqar, S., Zeman, K., Neal, J., Liang, C., Harrow, K., Holzhausen, A., Zhou, J., Selvaggi, G., Horn, et al
ELSEVIER SCIENCE INC.2019: S566
 - **Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions**
Jaenne, P., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., Costa, D. B., Tsao, A., Patel, J., Gadgeel, S., Bazhenova, L., Zhu, V. W., West, et al
OXFORD UNIV PRESS.2019
 - **Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK337794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study**
Reckamp, K. L., Akerley, W., Calvo, E., Clarke, J., Edelman, M. J., He, K., Moreno, V., Neal, J. W., Owonikoko, T. K., Patel, J. D., Patel, S. P., Riess, J. W., Sacher, et al
OXFORD UNIV PRESS.2019: 657-+
 - **Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions**
Riely, G., Neal, J., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., Costa, D., Tsao, A., Patel, J., Gadgeel, S., Bazhenova, L., Zhu, V., West, et al
ELSEVIER SCIENCE INC.2019: S412–S413
 - **The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging**
Ko, R., Therkelsen, K., Von Eyben, R., Neal, J., Loo, B., Nagpal, S.
ELSEVIER SCIENCE INC.2019: S585–S586
 - **A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens**
Karacosta, L., Anchang, B., Ignatiadis, N., Kimmey, S., Benson, J., Shrager, J., Sung, A., Neal, J., Wakelee, H., Tibshirani, R., Bendall, S., Plevritis, S.
ELSEVIER SCIENCE INC.2019: S226–S227
 - **STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC**
Skoulidis, F., Arbour, K., Hellmann, M., Patil, P., Marmarelis, M., Owen, D., Awad, M., Murray, J., Levy, B., Hellyer, J., Gainor, J., Stewart, T., Goldberg, et al
ELSEVIER SCIENCE INC.2019: S294–S295
 - **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**

- Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption** *JAMA DERMATOLOGY*
Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., Kwong, B. Y.
2019; 155 (7): 848–50
 - **A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer**
Reckamp, K. L., Akerley, W., Edelman, M. J., Halmos, B., He, K., Johnson, M., Mudad, R., Neal, J. W., Owonikoko, T. K., Patel, J. D., Patel, S. P., Riess, J. W., Sacher, et al
AMER ASSOC CANCER RESEARCH.2019
 - **Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients**
Liu, X., Ao, Z., Preiss, J. S., Neal, J., Zhou, L., Sambucetti, L., Wakelee, H. A.
AMER ASSOC CANCER RESEARCH.2019
 - **Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study** *ONCOLOGIST*
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., Neal, J. W.
2019; 24 (6): 836–43
 - **Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib** *ANTI-CANCER DRUGS*
Wang, S. X. Y., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M., Diehn, M., Kunder, C. A., Neal, J. W.
2019; 30 (5): 537–41
 - **Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., Van Den Heuvel, M., Neal, J., Peled, et al
2019
 - **Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.**
Janne, P. A., Neal, J. W., Camidge, D., Spira, A. I., Piotrowska, Z., Horn, L., Costa, D., Tsao, A. S., Patel, J. D., Gadgeel, S. M., Bazhenova, L., Zhu, V., West, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.**
Chaft, J. E., Costa, D., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., Ramchandran, K., Rangachari, D., Huberman, M., Piotrowska, Z., Kris, M. G., Azzoli, C. G., Sequist, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.**
Neal, J. W., Hausrath, D., Wakelee, H. A., Cunanan, K., Liu, S. V., Banwait, M., Sequist, L. V., Stirling, K., Piotrowska, Z.
AMER SOC CLINICAL ONCOLOGY.2019
 - **ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.**
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., He, J., Qiao, Y., Heymach, J., Tsao, A. S., Liao, Z. X., Gomez, D., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Increased Galectin-1 Expression in Thymic Epithelial Tumors** *CLINICAL LUNG CANCER*
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., Le, Q.
2019; 20 (3): E356–E361
 - **Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Sun, T. Y., Sung, A. W., Neal, J. W.

2019; 14 (4): e75-e77

- **Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis** *JOURNAL OF THORACIC ONCOLOGY*
Sun, T., Sung, A. W., Neal, J. W.
2019; 14 (4): E75–E77
- **Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC.**
Shah, A., Padda, S. K., Neal, J. W.
AMER SOC CLINICAL ONCOLOGY.2019
- **Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer** *CLINICAL LUNG CANCER*
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., Wakelee, H. A.
2019; 20 (2): E208–E217
- **Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.** *Anti-cancer drugs*
Wang, S. X., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M., Diehn, M., Kunder, C. A., Neal, J. W.
2019
- **Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Sun, T., Niu, X., Chakraborty, A., Neal, J. W., Wakelee, H. A.
2019; 14 (2): E21–E24
- **Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".** *Lung cancer (Amsterdam, Netherlands)*
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., Wakelee, H. A.
2019
- **Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M. n., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M. n., Ramchandran, K. J., Neal, J. W., Wakelee, H. A., Loehrer, P. J.
2019; 137: 71–75
- **Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Jeong, Y. n., Hellyer, J. A., Stehr, H. n., Hoang, N. T., Niu, X. n., Das, M. n., Padda, S. K., Ramchandran, K. n., Neal, J. W., Wakelee, H. A., Diehn, M. n.
2019
- **Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption.** *JAMA dermatology*
Hirotsu, K. n., Dang, T. M., Li, S. n., Neal, J. W., Pugliese, S. n., Subramanian, A. n., Kwong, B. Y.
2019
- **Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.** *Lung cancer (Amsterdam, Netherlands)*
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., Wakelee, H. A.
2019; 133: 144–50
- **Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Stehr, H. n., Das, M. n., Padda, S. K., Ramchandran, K. n., Neal, J. W., Diehn, M. n., Wakelee, H. A.
2019; 134: 42–45
- **Increased Galectin-1 Expression in Thymic Epithelial Tumors.** *Clinical lung cancer*
Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., Le, Q.
2018

- **EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Marcoux, N., Gettinger, S. N., O'Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., Del Prete, S., Wurtz, A., Farago, et al
2018: JCO1801585
- **SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., Evans, T. L., Costa, D. B., Wakelee, H. A., Heist, R. S., Shapiro, M. A., Muzikansky, A., Murthy, et al
2018: JCO1800131
- **Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam** *JOURNAL OF GLOBAL ONCOLOGY*
Nguyen, K. H., Stehr, H., Zhou, L., Anh-Hoa Nguyen, Pham Nhu Hiep, Nguyen Van Cau, Phan Canh Duy, Thorp, R., Wakelee, H. A., Diehn, M., Neal, J. W.
2018; 4
- **Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.** *Journal of global oncology*
Nguyen, K. H., Stehr, H., Zhou, L., Nguyen, A., Hiep, P. N., Van Cau, N., Duy, P. C., Thorp, R., Wakelee, H. A., Diehn, M., Neal, J. W.
2018: 1–9
- **EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.** *JCO precision oncology*
Goldman, J. W., Karlovich, C., Sequist, L. V., Melnikova, V., Franovic, A., Gadgeel, S. M., Reckamp, K. L., Camidge, D. R., Pérol, M., Ou, S. I., Liu, S. V., Yu, H. A., Soria, et al
2018; 2: 1-13
- **Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts)**
Wolf, J., Baik, C., Heist, R. S., Neal, J. W., Mansfield, A. S., Buettner, R., Davis, K. L., Giovannini, M., Mutebi, A., Awad, M. M.
ELSEVIER SCI LTD.2018: E131
- **Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.** *Clinical lung cancer*
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., Wakelee, H. A.
2018
- **Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center**
Myall, N., Henry, S., Wood, D., Neal, J., Wakelee, H.
ELSEVIER SCIENCE INC.2018: S489–S490
- **Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Lam, V. K., Hong, D. S., Heymach, J. V., Blumenschein, G., Butler, M. O., Johnson, M., Creelan, B., Gainor, J. F., Govindan, R., Mudad, R., Neal, J., Brophy, F., Fang, et al
2018; 29 Suppl 8: viii731
- **Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials**
Lam, V. K., Hong, D. S., Heymach, J. V., Blumenschein, G., Butler, M. O., Johnson, M., Creelan, B., Gainor, J. F., Govindan, R., Mudad, R., Neal, J., Brophy, F., Fang, et al
OXFORD UNIV PRESS.2018
- **Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC**
Neal, J., Doebele, R., Riely, G., Spira, A., Horn, L., Piotrowska, Z., Costa, D., Zhang, S., Bottino, D., Zhu, J., Kerstein, D., Li, S., Janne, et al
ELSEVIER SCIENCE INC.2018: S599
- **Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., Wakelee, H. A.
2018

- **Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Zweig, J. R., Neal, J. W.
2018; 36 (26): 2677-+
- **Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer** *CLINICAL LUNG CANCER*
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., Diehn, M., Loo, B. W., Gensheimer, M. F.
2018; 19 (5): E581–E588
- **Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data**
Leal, T., Wakelee, H., Reckamp, K., Waqar, S., Patel, S., Blumenschein, G., Neal, J., Harrow, K., Holzhausen, A., Liang, C., Dukart, G., Horn, L.
ELSEVIER SCIENCE INC.2018: S156
- **Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data**
Leal, T., Wakelee, H., Reckamp, K., Waqar, S., Patel, S., Blumenschein, G., Neal, J., Harrow, K., Holzhausen, A., Liang, C., Dukart, G., Horn, L.
ELSEVIER SCIENCE INC.2018: S156
- **Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.** *Lung cancer (Amsterdam, Netherlands)*
Wang, S. X., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., Neal, J. W.
2018; 122: 187–91
- **Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations** *LUNG CANCER*
Wang, S. X. Y., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., Neal, J. W.
2018; 122: 187–91
- **The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A., Gandhi, L., Garon, E. B., Hellmann, M. D., Hirsch, F. R., Malik, et al
2018; 6: 75
- **Organoid-based characterization of patient tumors and microenvironments at single cell resolution**
Salahudeen, A. A., Zhu, J., Ju, J., Batish, A., Sutha, K., Neal, J. T., Giangarra, V., Montesclaros, L., Sapida, J., Sharifi, O., Lee, J., Zheng, G. X., Wagh, et al
AMER ASSOC CANCER RESEARCH.2018
- **Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Zweig, J. R., Neal, J. W.
2018: JCO2018788554
- **Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study** *CLINICAL CANCER RESEARCH*
Horn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A., Waqar, S. N., Gitlitz, B. J., Sanborn, R. E., Whisenant, J. G., Du, L., Neal, J. W., Gockerman, J. P., Dukart, et al
2018; 24 (12): 2771–79
- **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer**
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., Newman, A. M., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H., Das, et al
ELSEVIER SCIENCE INC.2018: E1–E2
- **First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC).**
Doebele, R., Riely, G. J., Spira, A. I., Horn, L., Piotrowska, Z., Costa, D., Neal, J. W., Zhang, S., Reichmann, W., Kerstein, D., Li, S., Janne, P. A.
AMER SOC CLINICAL ONCOLOGY.2018
- **Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).**

- Mazieres, J., Drilon, A. E., Mhanna, L., Milia, J., Lusque, A., Cortot, A. B., Mezquita, L., Thai, A., Couraud, S., Veillon, R., Mascaux, C., Schouten, R., Neal, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.**
Salahudeen, A., Zhu, J., Ju, J., Giangarra, V., Montesclaros, L., Sapida, J., Sharifi, O., Lee, J., Wagh, D., Collier, J., Neal, J. W., Padda, S., Wakelee, et al
AMER SOC CLINICAL ONCOLOGY.2018
 - **Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).**
Marcoux, N., Gettinger, S. N., O'Kane, G. M., Arbour, K., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P., Del Prete, S. A., Wurtz, A., Farago, et al
AMER SOC CLINICAL ONCOLOGY.2018
 - **Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors** *JOURNAL OF THORACIC IMAGING*
Padda, S. K., Terrone, D., Tian, L., Khuong, A., Neal, J. W., Riess, J. W., Berry, M. F., Hoang, C. D., Burt, B. M., Leung, A. N., Schwartz, E. J., Shrager, J. B., Wakelee, et al
2018; 33 (3): 176–83
 - **Antimicrobial resistance due to antibiotic use for EGFR inhibitor related papulopustular skin reaction**
Hirotsu, K., Subramanian, A., Neal, J., Li, S., Pugliese, S., Kwong, B.
ELSEVIER SCIENCE INC.2018: S176
 - **EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor** *JCO PRECISION ONCOLOGY*
Goldman, J. W., Karlovich, C., Sequist, L., Melnikova, V., Franovic, A., Gadgeel, S. M., Reckamp, K. L., Camidge, D., Perol, M., Ou, S., Liu, S., Yu, H. A., Soria, et al
2018; 2: 1–13
 - **Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer** *LUNG CANCER*
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., Rosovsky, R. P., Lilienbaum, R. C., Bastos, B. R., Huang, C., Johnson, M. L., Hesketh, P. J., Subramaniam, et al
2018; 117: 44–49
 - **Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.** *Clinical lung cancer*
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H. n., Neal, J. W., Diehn, M. n., Loo, B. W., Gensheimer, M. F.
2018
 - **Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors** *NEUROSURGERY*
Vaca, S., Connolly, I., Ho, C., Neal, J., Gephart, M.
2018; 82 (1): E6–E14
 - **Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.** *The oncologist*
Xie, L. n., Nagpal, S. n., Wakelee, H. A., Li, G. n., Soltys, S. G., Neal, J. W.
2018
 - **Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma**
Gao, R. W., Berry, M. F., Kunder, C. A., Khuong, A. A., Wakelee, H., Neal, J. W., Backhus, L. M., Shrager, J. B.
MOSBY-ELSEVIER.2017: 2092+
 - **Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer** *RADIOTHERAPY AND ONCOLOGY*
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C., Zhu, H., Eclov, N. C. W., To, J., Murphy, J. D., Wakelee, H. A., Neal, J. W., Le, Q., Hara, W. Y., Quon, A., Maxim, et al
2017; 125 (2): 338–43
 - **Response to Ensartinib in TKI Naive ALK plus NSCLC Patients**
Wakelee, H., Sanborn, R., Nieva, J., Waqar, S., Brzezniak, C., Bauman, J., Neal, J., Dukart, G., Tan, F., Harrow, K., Liang, C., Horn, L.

ELSEVIER SCIENCE INC.2017: S1826

- **A Phase 1b Study of Erlotinib and Mometinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung**
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Kawashima, J., Kong, S., Xin, Y., Huang, D., Wakelee, H.
ELSEVIER SCIENCE INC.2017: S2142–S2143
- **Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA**
Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., Martin, J., Merriott, D., Carter, J., Ayers, K., Mansfield, A., Jen, J., Ren, et al
ELSEVIER SCIENCE INC.2017: S1851
- **Molecular and Clinicopathologic Features Associated with PD-L1 Expression in Lung Adenocarcinoma**
Yang, S., Steiner, D., Berry, G. J., Neal, J. W., Zehnder, J. L., Kunder, C. A.
ELSEVIER SCIENCE INC.2017: 1009–10
- **Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer**
Xiang, M., Gensheimer, M. F., Maxim, P. G., Wakelee, H. A., Neal, J. W., Diehn, M., Loo, B. W.
ELSEVIER SCIENCE INC.2017: E504
- **Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer**
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C. N., Eclov, N., To, J., Murphy, J. D., Wakelee, H. A., Neal, J. W., Le, Q. T., Hara, W., Quon, A., Maxim, P. G., Graves, et al
ELSEVIER SCIENCE INC.2017: E456
- **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer**
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H. R., Das, M., Padda, S., Loo, et al
ELSEVIER SCIENCE INC.2017: S20–S21
- **Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome**
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., Carter, J. N., Azad, T. D., Padda, S., Gensheimer, M. F., Wakelee, H. A., Neal, J. W., Loo, et al
ELSEVIER SCIENCE INC.2017: S1–S2
- **Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer**
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., Carter, J. N., Merriott, D. J., Liu, C. L., Kurtz, D. M., Gensheimer, M. F., Shrager, J. B., Wakelee, et al
ELSEVIER SCIENCE INC.2017: S114
- **Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. *Neurosurgery***
Vaca, S. D., Connolly, I. D., Ho, C., Neal, J., Hayden Gephart, M.
2017
- **The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer *CANCER***
Chuang, J. C., Neal, J. W.
2017; 123 (15): 2798–2801
- **Novel systemic therapy against malignant pleural mesothelioma *TRANSLATIONAL LUNG CANCER RESEARCH***
Mancuso, M. R., Neal, J. W.
2017; 6 (3): 295–314
- **Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging**
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Zhou, L., Liu, C., Scherer, F., Kurtz, D. M., Esfahani, M. S., Say, C., Carter, et al
ELSEVIER SCIENCE INC.2017: E4
- **Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry *JOURNAL OF CLINICAL ONCOLOGY***
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., Remon-Masip, J., Janne, P. A., Awad, et al

2017; 35 (13): 1403-?

- **Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
El-Deiry, W. S., Taylor, B., Neal, J. W.
2017: e8–e15
- **Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib.** *International journal of radiation oncology, biology, physics*
Wang, S. X., Zhang, B., Wakelee, H. A., Diehn, M., Kunder, C., Neal, J. W.
2017; 98 (1): 239-?
- **CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)**
Reckamp, K. L., Wakelee, H. A., Patel, S., Blumenschein, G., Neal, J. W., Gitlitz, B., Waqar, S. N., Tan, F., Harrow, K., Horn, L.
OXFORD UNIV PRESS.2017
- **Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.** *Molecular diagnosis & therapy*
Costa, H. A., Neal, J. W., Bustamante, C. D., Zehnder, J. L.
2017
- **Elusive Target of Angiogenesis in Small-Cell Lung Cancer.** *Journal of clinical oncology*
Neal, J. W., Wakelee, H. A.
2017: JCO2016716084-?
- **ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.** *Journal of thoracic oncology*
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., Wakelee, H. A., Neal, J. W.
2017
- **Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.** *International journal of radiation oncology, biology, physics*
Choi, C. Y., Wakelee, H. A., Neal, J. W., Pinder-Schenck, M. C., Yu, H. M., Chang, S. D., Adler, J. R., Modlin, L. A., Harsh, G. R., Soltys, S. G.
2017; 99 (1): 16–21
- **Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.** *Cancer discovery*
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H. n., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L. n., Scherer, F. n., Kurtz, D. M., Say, et al
2017
- **Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer**
Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., Carter, J., Zhou, L., West, R., Shrager, J., Neal, J., Wakelee, H., Loo, et al
ELSEVIER SCIENCE INC.2017: S445
- **A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma**
Wakelee, H., Melnikova, V., Karlovich, C., Gadgeel, S., Reckamp, K., Goldman, J. W., Camidge, D., Perol, M., Ou, S., Liu, S., Yu, H., Socinski, M., Mekhai, et al
ELSEVIER SCIENCE INC.2017: S384–S385
- **Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)**
Doebele, R., Horn, L., Spira, A., Piotrowska, Z., Costa, D., Neal, J., Reichmann, W., Kerstein, D., Li, S., Janne, P.
ELSEVIER SCIENCE INC.2017: S1072–S1073
- **A Phase Ib Study of Erlotinib and Mometinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer**
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Brachmann, C., Kawashima, J., Kong, S., Xin, Y., Huang, D., Wakelee, H.
ELSEVIER SCIENCE INC.2017: S1070–S1071
- **A Phase II Study of Etiprotectin Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer**
Nagpal, S., Wakelee, H., Padda, S., Bertrand, S., Acevedo, B., Tisch, A., Pagtama, J., Soltys, S., Neal, J.
ELSEVIER SCIENCE INC.2017: S940
- **Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC**

- Horn, L., Wakelee, H., Reckamp, K., Blumenschein, G., Infante, J., Carter, C., Waqar, S., Neal, J., Gockerman, J., Harrow, K., Dukart, G., Liang, C., Gibbons, et al
ELSEVIER SCIENCE INC.2017: S1159
- **Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting*
El-Deiry, W. S., Taylor, B., Neal, J. W.
2017; 37: e8–e15
 - **Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC**
Horn, L., Wakelee, H., Reckamp, K., Blumenschein, G., Infante, J., Carter, C., Waqar, S., Neal, J., Gockerman, J., Harrow, K., Dukart, G., Liang, C., Gibbons, et al
ELSEVIER SCIENCE INC.2017: S1159
 - **Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting*
El-Deiry, W. S., Taylor, B., Neal, J. W.
2017; 37: e8–e15
 - **Molecular profiling of single circulating tumor cells from lung cancer patients** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Park, S., Wong, D. J., Ooi, C. C., Kurtz, D. M., Vermesh, O., Aalipour, A., Suh, S., Pian, K. L., Chabon, J. J., Lee, S. H., Jamali, M., Say, C., Carter, et al
2016; 113 (52): E8379-E8386
 - **Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial** *LANCET ONCOLOGY*
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., Owonikoko, T. K., Stella, P. J., Steen, et al
2016; 17 (12): 1661-1671
 - **Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.** *Nature communications*
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., Harding, T. C., Durkin, K. A., Otterson, et al
2016; 7: 13513-?
 - **PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology.** *Journal of thoracic oncology*
Wang, S. X., Zhang, B. M., Wakelee, H., Diehn, M., Kunder, C. A., Neal, J. W.
2016; 11 (11S): S312-S313
 - **PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology.** *Journal of thoracic oncology*
Salahudeen, A., De La O, S., Padda, S. K., Neal, J. W., Wakelee, H., Kuo, C.
2016; 11 (11S): S282-?
 - **PS01.04: A Phase II Study of Etiprotectin Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology.** *Journal of thoracic oncology*
Neal, J. W., Wakelee, H., Padda, S. K., Bertrand, S., Acevedo, B., Holmes Tisch, A., Pagtama, J. Y., Soltys, S. G., Nagpal, S.
2016; 11 (11S): S271-S272
 - **MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology.** *Journal of thoracic oncology*
Horn, L., Wakelee, H., Reckamp, K. L., Blumenschein, G., Infante, J. R., Carter, C. A., Waqar, S. N., Neal, J. W., Harrow, K., Gockerman, J. P., Dukart, G., Liang, C., Gibbons, et al
2016; 11 (11S): S256-S257
 - **Rociletinib-associated cataracts in EGFR-mutant NSCLC**
Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S. V., Neal, J., Spiegel, M., Solomon, B., Yu, H., Ou, S. I., Papadimitrakopoulou, V. A., Gadgeel, et al
OXFORD UNIV PRESS.2016

- **CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer**
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., Aggarwal, S., Carter, J. N., West, R. B., Neal, J. W., Wakelee, H. A., Loo, B. W., Alizadeh, et al
ELSEVIER SCIENCE INC.2016: S41–S42
- **Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)**
Horn, L., Wakelee, H., Blumenschein, G., Reckamp, K., Waqar, S., Carter, C. A., Gitlitz, B. J., Infante, J. R., Sanborn, R. E., Neal, J., Gockerman, J. P., Dukart, G., Harrow, et al
OXFORD UNIV PRESS.2016
- **Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.** *Journal of oncology practice / American Society of Clinical Oncology*
Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., Hofmann, L. V., Neal, J. W., Telli, M. L.
2016; 12 (8): 763-764
- **Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.** *Clinical therapeutics*
Chuang, J. C., Shrager, J. B., Wakelee, H. A., Neal, J. W.
2016; 38 (7): 1567-1576
- **Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients** *NATURE COMMUNICATIONS*
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., Harding, T. C., Durkin, K. A., Otterson, et al
2016; 7
- **Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.**
Chabon, J., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., Kurtz, D., Stehr, H., Scherer, F., Durkin, K. A., Otterson, G., Purcell, W. T., Camidge, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.**
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D., Chabon, J. J., Scherer, F., Stehr, H., Liu, C., Bratman, S., Say, C., Zhou, L., Carter, J. N., West, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC).**
Horn, L., Wakelee, H. A., Reckamp, K. L., Blumenschein, G. R., Infante, J. R., Carter, C., Waciar, S., Neal, J. W., Gockerman, J. P., Harrow, K., Dukart, G., Liang, C., Gibbons, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.**
Wakelee, H. A., Gadgeel, S. M., Goldman, J., Reckamp, K. L., Karlovich, C., Melnikova, V., Soria, J., Yu, H., Solomon, B. J., Perol, M., Neal, J. W., Liu, S. V., Raponi, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Integrated digital error suppression for improved detection of circulating tumor DNA** *NATURE BIOTECHNOLOGY*
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., Zhou, L., Carter, J. N., West, et al
2016; 34 (5): 547-555
- **Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.** *Clinical lung cancer*
Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., Diehn, M., Wakelee, H. A.
2016; 17 (2): e17-21
- **Pruritus as a Paraneoplastic Symptom of Thymoma** *JOURNAL OF THORACIC ONCOLOGY*
Padda, S. K., Shrager, J. B., Riess, J. W., Pagtama, J. Y., Tisch, A. J., Kwong, B. Y., Liang, Y., Schwartz, E. J., Loo, B. W., Neal, J. W., Hardy, R., Wakelee, H. A.

2015; 10 (11): E110-E112

- **Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial**
Modlin, L. A., Choi, C. H., Gibbs, I. C., Wakelee, H. A., Neal, J., Pinder-Schenck, M. C., Chang, S. D., Adler, J. R., Harsh, G. R., Soltys, S. G.
ELSEVIER SCIENCE INC.2015: S178
- **Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.** *Translational lung cancer research*
Chuang, J. C., Neal, J. W.
2015; 4 (5): 639-641
- **Management of Dermatologic Complications of Lung Cancer Therapies.** *Current treatment options in oncology*
Pugliese, S. B., Neal, J. W., Kwong, B. Y.
2015; 16 (10): 50-?
- **Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.** *American journal of ophthalmology*
Leung, L. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., Marmor, M. F.
2015; 160 (4): 799-805 e1
- **Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.** *Lung cancer*
Chuang, J. C., Neal, J. W., Niu, X., Wakelee, H. A.
2015; 90 (1): 1-7
- **Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.** *American journal of ophthalmology*
Leung, L. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., Marmor, M. F.
2015; 160 (4): 799-805 e1
- **Management of Dermatologic Complications of Lung Cancer Therapies.** *Current treatment options in oncology*
Pugliese, S. B., Neal, J. W., Kwong, B. Y.
2015; 16 (10): 368-?
- **Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction** *LUNG CANCER*
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., Wakelee, H. A.
2015; 89 (3): 280-286
- **Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.** *Clinical lung cancer*
Liang, Y., Wakelee, H. A., Neal, J. W.
2015; 16 (5): 366-73
- **Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.** *Lung cancer (Amsterdam, Netherlands)*
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., Wakelee, H. A.
2015; 89 (3): 280-6
- **A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512**
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., Ramalingam, S. S.
ELSEVIER SCIENCE INC.2015: S373
- **Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies**
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M., Ramchandran, K. J., Gubens, M. A., Neal, J. W., Loehrer, P. J.
ELSEVIER SCIENCE INC.2015: S195
- **VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus +/- Erlotinib in Non-Small Cell Lung Cancer**
Padda, S. K., Lara, P., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H., Zhou, L. Y., Subramaniam, D. S., Leach, J. W., Wax, M. B., Neal, J. W., Clary, D. O., Goodman, et al
ELSEVIER SCIENCE INC.2015: S291
- **Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies**
Chuang, J., Neal, J. W., Wakelee, H. A.

ELSEVIER SCIENCE INC.2015: S549

- **Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma**
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., Berry, M., Leung, A. N., Schwartz, E. J., Shrager, J. B., Wakelee, H. A.
ELSEVIER SCIENCE INC.2015: S196
- **Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*
Liang, Y., Wakelee, H. A., Neal, J. W.
2015; 16 (5): 366-373
- **Improved survival among lung cancer patients taking antidepressants**
Zingone, A., Brown, D., Bowman, E., Vidal, O., Neal, J., Sage, J., Ryan, B. M.
AMER ASSOC CANCER RESEARCH.2015
- **Heterogeneity Underlies the Emergence of EGFR T790M Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.** *Cancer discovery*
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., Fulton, L., Hata, A. N., Lockerman, E. L., Kalsy, A., Digumarthy, S., Muzikansky, A., Raponi, et al
2015; 5 (7): 713-722
- **Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).**
Neal, J. W., Dahlberg, S., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D., Ramalingam, S. S.
AMER SOC CLINICAL ONCOLOGY.2015
- **Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).**
Wakelee, H. A., Padda, S., Burns, M., Spittler, A., Riess, J., San Pedro-Salcedo, M., Ramchandran, K., Gubens, M. A., Neal, J. W., Loehrer, P. J.
AMER SOC CLINICAL ONCOLOGY.2015
- **Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer** *NEW ENGLAND JOURNAL OF MEDICINE*
Sequist, L. V., Soria, J., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., SOLOMON, B. J., Oxnard, G. R., Dziadziuszko, R., Aisner, D. L., Doebele, R. C., Galasso, et al
2015; 372 (18): 1700-1709
- **Developing biomarker-specific end points in lung cancer clinical trials** *NATURE REVIEWS CLINICAL ONCOLOGY*
Neal, J. W., Gainor, J. F., Shaw, A. T.
2015; 12 (3): 135-146
- **Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.** *Journal of thoracic oncology*
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., West, R. B., Wakelee, H. A.
2015; 10 (3): 500-508
- **Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.** *Proceedings of the National Academy of Sciences of the United States of America*
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., Gandhi, L., Lynch, T. J., Engelman, et al
2015; 112 (5): 1547-1552
- **GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.** *Anticancer research*
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., Wakelee, H. A.
2015; 35 (2): 669-676
- **GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray.** *Anticancer research*
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., Wakelee, H. A.
2015; 35 (2): 669-676
- **Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.** *Lung cancer*
Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., Wakelee, H. A.
2015; 87 (1): 34-38
- **Unicentric, multifocal castleman disease of the mediastinum associated with cerebellitis.** *Annals of thoracic surgery*

Hamaji, M., Neal, J. W., Burt, B. M.
2015; 99 (1): e7-9

- **Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing**
Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, A.
ELSEVIER SCIENCE INC.2014: S75
- **Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)**
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., Rosovsky, R., Lilenbaum, R., Bastos, B. R., Huang, C., Johnson, M. L., Hasketh, P. J., Subramaniam, et al
ELSEVIER SCIENCE INC.2014: S36
- **Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.** *Nature reviews. Clinical oncology*
Neal, J. W., Sledge, G. W.
2014; 11 (11): 627-628
- **Review of the current targeted therapies for non-small-cell lung cancer.** *World journal of clinical oncology*
Nguyen, K. H., Neal, J. W., Wakelee, H.
2014; 5 (4): 576-587
- **Review of the current targeted therapies for non-small-cell lung cancer** *WORLD JOURNAL OF CLINICAL ONCOLOGY*
Nguyen, K. H., Neal, J. W., Wakelee, H.
2014; 5 (4): 576–87
- **A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors**
Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., Zmoos, A., Vaka, D., Tran, K. Q. T., Zhou, M., Krasinska, K., Riess, J. W., Neal, et al
AMER ASSOC CANCER RESEARCH.2014
- **PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY**
Liang, Y., Padda, S., Riess, J. W., West, R., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2014: S226
- **Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC**
Modlin, L. A., Bratman, S. V., Newman, A. M., Eclow, N. W., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Alizadeh, A. A., Diehn, M.
ELSEVIER SCIENCE INC.2014: S812
- **COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAKA-KOGA PATHOLOGIC STAGE IN THYMOMA**
Padda, S., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., Hoang, C. D., Burt, B. M., Leung, A. N., Shrager, J. B., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2014: S222
- **PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA**
Padda, S., Pagtama, J. Y., Tisch, A. H., Neal, J. W., Riess, J. W., Loo, B. W., Hardy, R., Shrager, J. B., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2014: S240–S241
- **PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA)**
Padda, S., Riess, J. W., Schwartz, E., Tian, L., Kohrt, H., Neal, J. W., West, R., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2014: S212
- **Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA)**
Padda, S., Riess, J., Schwartz, E., Tian, L., Kohrt, H., Neal, J. W., Natkunam, Y., West, R. B., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2014
- **SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.**
Pennell, N. A., Neal, J. W., Chaff, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., Evans, T. L., Costa, D., Rosovsky, R., Wakelee, H. A., Heist, R., Shaw, A., Temel, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.**
Bratman, S., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Diehn, M., Alizadeh, A. A.

AMER SOC CLINICAL ONCOLOGY.2014

- **A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)**
Neal, J. W., Wakelee, H. A., Feliciano, J., Goldberg, S. B., Morgensztern, D., Das, M., Heist, R., Lennes, I., Muzikansky, A., Edelman, M. J., Gettinger, S. N., Sequist, L. V.
AMER SOC CLINICAL ONCOLOGY.2014
- **An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.** *Nature medicine*
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al
2014; 20 (5): 548-554
- **An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage** *NATURE MEDICINE*
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al
2014; 20 (5): 552-558
- **Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.** *Clinical lung cancer*
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., Neal, J. W., Wakelee, H. A.
2014; 15 (3): 202-206
- **Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.** *Immunopharmacology and immunotoxicology*
Riess, J. W., Bhattacharya, N., Blenman, K. R., Neal, J. W., Hwang, G., Pultar, P., San-Pedro Salcedo, M., Engleman, E., Lee, P. P., Malik, R., Wakelee, H. A.
2014; 36 (2): 182-186
- **A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.** *British journal of cancer*
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., Leigh, N. B., Riess, J. W., Kuo, C. J., Liu, L., Gao, B., DiCioccio, A. T., Adjei, et al
2014; 110 (3): 602-608
- **Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.** *Archives of pathology & laboratory medicine*
Cagle, P. T., Sholl, L. M., Lindeman, N. I., Alsabeh, R., Divaris, D. X., Foulis, P., Lee, G., Neal, J. W., Nowak, J. A., Yu, P. P.
2014; 138 (2): 171-174
- **A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer.**
Jahchan, N., Joel, D., Mazur, P., Neal, J., Khatri, P., Butte, A., Sage, J.
AMER ASSOC CANCER RESEARCH.2014
- **Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips** *LAB ON A CHIP*
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., Humke, E. W., Xu, L., Wong, D. J., Willingham, S. B., Schwartz, E. J., Weissman, I. L., Jeffrey, et al
2014; 14 (1): 78-88
- **Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.** *Lab on a chip*
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., Humke, E. W., Xu, L., Wong, D. J., Willingham, S. B., Schwartz, E. J., Weissman, I. L., Jeffrey, et al
2013; 14 (1): 78-88
- **ENERGY METABOLISM IN LUNG ADENOCARCINOMA**
Hoang, C., Xu, Y., Shi, Z., Lin, Y., Merritt, R. E., Shrager, J., Das, M., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1036-S1037
- **ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION**
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1185-S1186

- **PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER**
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., Harman, S., Dwyer, P., Bosch, J., Shaw, H., Safari, S., Oden, R., Morrison, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S1324
- **VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS**
Nguyen, K. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., Burt, B., Tisch, A., Pagtama, J., Zehnder, J., Berry, G., Wakelee, H. A., Anh-Hoa Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S208–S209
- **FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)**
Soria, J., Sequist, L. V., Gadgeel, S., Goldman, J., Wakelee, H., Varga, A., Fidias, P., Wozniak, A. J., Neal, J. W., Doebele, R. C., Garon, E. B., Jaw-Tsai, S., Caunt, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S141–S142
- **STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES**
Wakelee, H. A., Riess, J. W., San Pedro-Salcedo, M., Padda, S. K., Ramchandran, K., Gubens, M. A., Neal, J. W.
LIPPINCOTT WILLIAMS & WILKINS.2013: S731
- **GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)**
Riess, J. W., West, R., Padda, S. K., Dean, M., Klimowicz, A., Huong, C., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S944
- **CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)**
Padda, S. K., Rosenberg-Hasson, Y., Neal, J. W., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H. L., Subramaniam, D., Leach, J. W., Lara, P. N., Wax, M. B., Wakelee, H. A., Clary, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S1072–S1073
- **Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. *Translational lung cancer research***
Neal, J. W., Sequist, L. V.
2013; 2 (5): 411-414
- **Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond *TRANSLATIONAL LUNG CANCER RESEARCH***
Neal, J. W., Sequist, L. V.
2013; 2 (5): 411–14
- **Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing**
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., Shrager, J., Loo, B. W., Alizadeh, A. A., Diehn, M.
ELSEVIER SCIENCE INC.2013: S92
- **A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. *Clinical lung cancer***
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., Cherry, A., Wakelee, H. A.
2013; 14 (5): 592-595
- **GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)**
Riess, J., West, R., Padda, S., Dean, M., Klimowicz, A., Huong, C., Neal, J., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2013: 25
- **STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES**
Wakelee, H., Riess, J., Pedro-Salcedo, M., Padda, S., Ramchandran, K., Gubens, M., Neal, J.
LIPPINCOTT WILLIAMS & WILKINS.2013: 22–23

- **First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.**
Sequist, L. V., Soria, J., Gadgeel, S. M., Wakelee, H. A., Camidge, D., Varga, A., Fidias, P., Wozniak, A. J., Neal, J. W., Doebele, R., Garon, E. B., Jaw-Tsai, S. S., Stern, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Riess, J. W., Nagpal, S., Neal, J. W., Wake, H. A.
2013; 11 (4): 389-394
- **A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.** *Journal of thoracic oncology*
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., Wakelee, H. A.
2013; 8 (2): e17-8
- **A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab** *JOURNAL OF THORACIC ONCOLOGY*
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., Wakelee, H. A.
2013; 8 (2): E17-E18
- **Aflibercept in lung cancer** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Neal, J. W., Wakelee, H. A.
2013; 13 (1): 115-120
- **Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.** *Journal of thoracic oncology*
Riess, J. W., Neal, J. W.
2012; 7 (16): S385-6
- **MET inhibitors in combination with other therapies in non-small cell lung cancer** *TRANSLATIONAL LUNG CANCER RESEARCH*
Padda, S., Neal, J. W., Wakelee, H. A.
2012; 1 (4): 238–53
- **MET inhibitors in combination with other therapies in non-small cell lung cancer.** *Translational lung cancer research*
Padda, S., Neal, J. W., Wakelee, H. A.
2012; 1 (4): 238-253
- **Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer** *54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Bratman, S. V., Eclow, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu, G., Richardson, K., Newman, A. M., Alizadeh, A., Diehn, M.
ELSEVIER SCIENCE INC.2012: S713–S713
- **A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Goldberg, S. B., Supko, J. G., Neal, J. W., Muzikansky, A., Digumarthy, S., Fidias, P., Temel, J. S., Heist, R. S., Shaw, A. T., McCarthy, P. O., Lynch, T. J., Sharma, S., Settleman, et al
2012; 7 (10): 1602-1608
- **Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era**
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2012: S243–S243
- **The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC)**
Neal, J. W., Pennell, N. A., Govindan, R., Heist, R. S., Shaw, A. T., Muzikansky, A., Janne, P. A., Lynch, T. J., Azzoli, C. G., Sequist, L. V.
LIPPINCOTT WILLIAMS & WILKINS.2012: S209–S209
- **A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours** *BRITISH JOURNAL OF CANCER*
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R., Colevas, A. D., Shepherd, F. A., Leighl, N. B., Neal, J. W., Thibault, A., Liu, L., Lisano, J., Gao, B., Lawson, et al
2012; 107 (4): 604-611

- **Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Neal, J. W., Sequist, L. V.
2012; 30 (18): 2280-2282
- **Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study** *JOURNAL OF CLINICAL ONCOLOGY*
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J., Reck, M.
2012; 30 (17): 2046-2054
- **A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., Leigh, N. B., Liu, L., Lisano, J. M., Adjei, A. A., Wakelee, H. A.
AMER SOC CLINICAL ONCOLOGY.2012
- **The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Neal, J. W., Pennell, N. A., Govindan, R., Lanuti, M., Rosovsky, R. P., Heist, R. S., Shaw, A. T., Temel, J. S., Muzikansky, A., Janne, P. A., Lynch, T. J., Azzoli, C. G., Sequist, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms**
Davidzon, G., Wakelee, H., Neal, J., Mitra, E., Quon, A., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2012
- **First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.** *Biologics : targets & therapy*
Nguyen, K. H., Neal, J. W.
2012; 6: 337-345
- **First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors** *BIOLOGICS-TARGETS & THERAPY*
Nguyen, K. H., Neal, J. W.
2012; 6: 337-45
- **Current Management of Small Cell Lung Cancer** *CLINICS IN CHEST MEDICINE*
Neal, J. W., Gubens, M. A., Wakelee, H. A.
2011; 32 (4): 853-?
- **Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Riess, J. W., Neal, J. W.
2011; 6 (11): S1797-S1798
- **Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC**
Heist, R. S., Duda, G. D., Sahani, D., Ancukiewicz, M., Fidias, P., Sequist, L. V., Shaw, A. T., Temel, J. S., Lennes, I. T., Neal, J. W., Pennell, N. A., Lynch, T. J., Engelman, et al
AMER SOC CLINICAL ONCOLOGY.2011
- **One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer** *CLINICAL CANCER RESEARCH*
Neal, J. W., Shaw, A. T.
2011; 17 (4): 638-639
- **Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC** *ONCOLOGIST*
Mak, R. H., Doran, E., Muzikansky, A., Kang, J., Neal, J. W., Baldini, E. H., Choi, N. C., Willers, H., Jackman, D. M., Sequist, L. V.
2011; 16 (6): 886-895
- **The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer** *FUTURE ONCOLOGY*
Neal, J. W.
2010; 6 (12): 1827-1832

- **Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.** *Journal of thoracic oncology*
Neal, J. W., Heist, R. S., Fidias, P., Temel, J. S., Huberman, M., Marcoux, J. P., Muzikansky, A., Lynch, T. J., Sequist, L. V.
2010; 5 (11): 1855-1858
- **AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer** *CURRENT OPINION IN MOLECULAR THERAPEUTICS*
Neal, J., Wakelee, H.
2010; 12 (4): 487-495
- **Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Neal, J. W., Sequist, L. V.
2010; 11 (1-2): 36-44
- **Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.** *Nature reviews. Clinical oncology*
Neal, J. W., Sequist, L. V.
2010; 7 (2): 71-72
- **First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.** *Clinical advances in hematology & oncology : H&O*
Neal, J. W., Sequist, L. V.
2010; 8 (2): 119-126
- **Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells** *BLOOD*
Barry, S. M., Zisoulis, D. G., Neal, J. W., Clipstone, N. A., Kansas, G. S.
2003; 102 (5): 1771-1778
- **A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Neal, J. W., Clipstone, N. A.
2003; 278 (19): 17246-17254
- **Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Neal, J. W., Clipstone, N. A.
2002; 277 (51): 49776-49781
- **Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Neal, J. W., Clipstone, N. A.
2001; 276 (5): 3666-3673
- **REGULATION OF THE GLUCOSE-H⁺ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS** *JOURNAL OF BACTERIOLOGY*
Ye, J. J., Neal, J. W., Cui, X. W., Reizer, J., Saier, M. H.
1994; 176 (12): 3484-3492